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Summary 
 
 
Section A: Cognitive Functioning and Health Related Quality of Life in Patients with 
Primary Antiphospholipid Syndrome 
 
This paper reviews the literature surrounding cognitive functioning in patients with 
Antiphospholipid syndrome (APS) in the context of quality of life as an indicator of 
adaptation to chronic illness. The review focuses on cognitive functioning in APS patients and 
related clinical populations, describing and critiquing the empirical research literature 
exploring the evidence for cognitive deficits in these populations.  Psychological theories of 
adaptation to chronic illness are discussed in relation to the concept of quality of life and 
research examining the relationship between cognitive dysfunction in APS and related clinical 
populations and health- related quality of life (HRQoL) is summarised. The limitations of 
previous research examining these factors are highlighted, demonstrating the need for 
empirical studies that address cognitive functioning and quality of life in patients with 
primary APS (PAPS). 
 
Section B: The Relationship of Cognitive Functioning and Health Related Quality of Life in 
Patients with Primary Antiphospholipid Syndrome 
 
This study investigated the relationship between cognitive functioning and HRQoL in patients 
with PAPS. A cross-sectional design was used. Participants were recruited from a large 
London medical centre where assessment involved the completion of a questionnaire 
measuring HRQoL and a comprehensive battery of neuropsychological tests of general 
intelligence, memory and executive functioning.  
 
Section C: Critical Appraisal  
 
The critical review is structured to address four specific questions providing a reflective 
account of how the involvement in this project has contributed to the researcher’s skills and 
abilities and highlighted areas where further learning is necessary. The review also discusses 
further clinical applications and research for cognitive functioning and HRQoL in patients 
with PAPS.  
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Abstract 
Antiphospholipid syndrome (APS) is an autoimmune disease and chronic illness characterised 
by thrombosis and recurrent pregnancy morbidity. It may occur as an isolated diagnosis, 
primary APS (PAPS), or it may be secondary, associated with other autoimmune disorders. A 
clinical feature of APS is cognitive dysfunction which may be a direct manifestation of 
central nervous system involvement. It may also be a secondary response to a diagnosis of a 
life-altering chronic illness. The psychosocial process of adapting to a chronic illness has 
become an important measure in health outcomes which relate specifically to health related 
quality of life (HRQoL). This review evaluates the literature on cognitive dysfunction and 
HRQoL in APS and demonstrates the need for further empirical research in this clinical 
population to inform the development of treatment approaches and health outcomes for those 
with APS. Where PAPS is considered the pure form of the disease, future research should 
endeavour to include this specific group. 
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 1. OVERVIEW  
 
Antiphospholipid Syndrome (APS) is a recently described autoimmune disorder with a 
vast range of clinical features. While progress has been made in terms of the science of the 
disease (Lockshin, 2006) and recognition of the condition has grown, health professionals in 
general are still largely unaware of it (Donnan & McDonald, 2009) and there remain many 
unanswered questions (Lockshin, 2006). Pharmacological interventions to treat and manage 
the symptoms of APS are established; however, the social, psychological and emotional 
experience of this illness, like many chronic illnesses, is important to consider in relation to 
health outcomes. Although poorly recognised and relatively unexplored (Gordon, 
Goldenberg, Erkan, & Lockshin, 2009; Pattanaik & Brey, 2006), one clinical manifestation of 
this disease, which may influence these experiences, is cognitive functioning.  
 
2. OBJECTIVES 
 
The purpose of this literature review is to explore cognitive functioning in APS 
patients in the context of quality of life as an indicator of adaptation to chronic illness. The 
review will follow a structure as follows: i) Clinical features of APS will be described, with a 
specific focus on cognitive functioning in APS patients and related clinical populations, ii) 
Empirical research literature exploring the evidence for cognitive deficits in these populations 
will be described and critiqued, iii)  Psychological theories of adaptation to chronic illness 
will then be discussed in relation to the concept of quality of life, iv) Research examining the 
relationship between cognitive dysfunction in APS and related clinical populations and 
health-related quality of life will be summarised.  Within this context, the limitations of 
previous research examining these factors will be highlighted, demonstrating the need for 
empirical studies that address cognitive functioning and quality of life in patients with APS. 
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3. METHOD 
 
The literature was searched in 2010 and 2011 using electronic databases to search for 
research articles published between 1980 and 2011. Details of the method including the 
selection procedure can be found in Appendix A.  
 
4. REVIEW 
 
4.1 Antiphospholipid Syndrome: An Autoimmune Disease and Chronic Illness 
 
4.4.1. Definition and clinical manifestations 
 
Antiphospholipid syndrome (APS), also known as Hughes’ syndrome was first 
recognised 26 years ago. APS is an autoimmune disease and is a prothrombotic condition. It 
is diagnosed on the basis of clinical and laboratory findings. There must be a presence of 
clinical event/s including venous/arterial thrombosis and/or pregnancy losses in association 
with laboratory blood tests confirming moderate-to-high titer antiphospholipid (aPL) 
antibodies (Miyakis et al., 2006).  APS may occur as an isolated diagnosis (primary APS; 
PAPS) or it may be secondary. It is secondary where individuals with other autoimmune 
disorders also have moderate-to-high titre aPL antibodies and/or the presence of the lupus 
anticoagulant. There is a high prevalence of APS among patients with Systemic lupus 
erythematosus (SLE) – also referred to as SLE-related APS (Tektonidou, Varsou, Kotoulas, 
Antoniou, & Moutsopoulos, 2006). 
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The clinical spectrum of APS features is extensive (D’Cruz, 2006) and there are no 
significant differences in the main clinical features whether the syndrome is primary (PAPS) 
or secondary (Vincent & Mackworth-Young, 2006). Clinical associations include: 
gastrointestinal, vascular disease, skin, bone, obstetric, renal, pulmonary, endocrine and 
haematological. Central Nervous System (CNS) involvement is one of the most common 
features of APS including neuropsychiatric manifestations such as stroke, seizures, cognitive 
dysfunction, migraine, transient ischaemic attack, chorea, psychosis, multiple-sclerosis (MS) 
like features, sensorineural hearing loss and mood disorders. Although common, not all 
patients with primary or secondary APS experience CNS involvement. 
  
Where PAPS and secondary APS are characterised by the presence of moderate-to-
high aPL antibodies, they can be present at low levels with an absence of clinical events 
(thrombosis and pregnancy losses) and therefore asymptomatic patients testing positive for 
aPL antibodies do exist. However, these patients can experience some of the neuropsychiatric 
syndromes that those with definite primary and secondary APS experience such as seizures, 
chorea, migraine and cognitive dysfunction (Erkan, Kozora, & Lockshin, 2011).  
 
4.1.2. Prevalence of APS 
 
The prevalence of aPL antibodies in otherwise healthy populations is less than 1% and 
up to 5% in older healthy populations and the prevalence increases with age (D’Cruz, 2006). 
At least twice as many women as men develop APS. This parallels other autoimmune 
connective-tissue diseases which have a female predominance. It is difficult to measure the 
number of people with APS. Studies indicate that between 5-40% of individuals with 
thrombosis and no history of SLE have aPL antibodies. Additional studies suggest that aPL 
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antibodies play a role in approximately 20% of strokes in individuals under the age of 40 
(Khamashta, 2006). Up to 30% of patients with SLE have aPL antibodies (D’Cruz, 2006).  
 
4.1.3. Diagnosis of APS 
 
APS is recognised as a common disorder and once diagnosed, is treatable. However, 
for many patients diagnosis is often delayed, sometimes for years, with consequent disability, 
loss of livelihood, inability to start a family or even death (D’Cruz, 2006). APS is often not 
defined until a clinical event has occurred, usually thrombosis (Vincent & Mackworth-Young, 
2006). Donnan and McDonald (2009) found that the median pre-diagnosis period for patients 
was 3 years. The most common diagnoses given were migraines (18.6%) and MS (12.7%). 
Other common diagnoses were miscarriages, SLE, stress, depression and anxiety.  
 
4.2. Cognitive Dysfunction: A Clinical Manifestation of APS 
 
4.2.1. Cognitive dysfunction in APS: overview 
 
Cognitive deficits associated with secondary APS and PAPS can vary from mild 
neurocognitive disorders to severe global dysfunction in the context of dementia. Although 
interest in this area has increased in recent years, research is limited and few formal 
neuropsychological studies have been conducted to assess the prevalence and nature of 
cognitive deficits in patients with APS (Pattanaik & Brey, 2006). Studies evaluating 
neurocognitive deficits have mainly included SLE patients testing positive for aPL antibodies 
(low aPL levels and no clinical events thereby not meeting criteria for APS). Research 
distinguishing secondary APS and PAPS patients specifically is more limited and mainly 
COGNITIVE FUNCTIONING AND HRQOL IN PATIENTS WITH PAPS 
 
 
 
 7 
anecdotal (Pattanaik & Brey, 2006). Findings so far have not identified any consistent pattern 
of cognitive dysfunction although there are similarities in the deficits found. When cognitive 
dysfunction is mild, patients complain of deficits in attention, difficulty concentrating on 
tasks, forgetfulness and other deficits that mildly interfere with everyday function. These less 
severe forms of cognitive impairment are considered common in patients with APS and may 
be the only clinical manifestation of APS being present independently of CNS involvement 
(Denburg, Carbotte, Ginsberg, & Denburg, 1997). 
 
The recognition of the subtle forms of cognitive dysfunction that may not have been 
identified by brief examination has been greatly facilitated by the application of 
neuropsychological assessment. Furthermore, neuropsychological tests have been sensitive 
enough to measure deficits in patients without any history of neuropsychiatric or CNS 
involvement e.g. stroke.  This has improved understanding about the nature of cognitive 
impairment in patients with APS, as well as the involvement of aPL antibodies on the CNS 
(Tektonidou, et al., 2006) and their ability to compromise it (Sanna, 2006). 
 
4.2.2. Cognitive dysfunction in APS and the role of psychological distress  
 
Emotional and psychological distress is common in patients with chronic diseases 
(Harrison & Ravdin, 2002) and is known to influence reports of cognitive functioning as well 
as performance on neuropsychological tests (Sweet, Newman, & Bell, 1992). The role of such 
variables has not been explored in patients with APS but it has been explored in relation to 
cognitive functioning in patients with SLE. The issue is complicated by controversy as to 
whether psychological factors, in particular, depression, are a direct manifestation of CNS 
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involvement or a secondary response to a chronic illness (Denburg, Carbotte, & Denburg, 
1987).  
 
In either instance, performance on neuropsychological tests may be affected. 
Some researchers argue that due to the high prevalence of distress in those with SLE, 
cognitive deficits can be attributed to the psychological factors of living with a chronic 
disease (Hutchinson, Nehall, & Simeon, 1996). However this is not supported by some 
studies exploring depressive symptoms in SLE patients and other chronic illnesses (Kozora, 
Thompson, West, & Kotzin, 1986). Kozora et al’s (1986) study demonstrated no relationship 
between the cognitive aspects of depression and neuropsychological test performance. This is 
supported by earlier research, also indicating no relationship between cognitive function in 
patients with SLE (including neuropsychiatric patients) and psychological distress (Carbotte, 
Denburg, & Denburg, 1986; Denburg et al., 1997; Glanz et al., 1997; Waterloo, Omdal, 
Mellgren, & Husby, 1997).  
 
Monastero et al. (2001), however, did find a significant relationship between 
depression and cognitive dysfunction in SLE patients with and without overt neuropsychiatric 
manifestations of disease compared with age-matched healthy controls. Post hoc analyses 
showed that the neuropsychiatric SLE patients performed more poorly than SLE patients 
without neuropsychiatric involvement, and both patient groups performed worse than 
controls. However, only the neuropsychiatric SLE patients differed significantly from the 
controls on measures of depression and anxiety. Multivariate analyses found that depression 
was the only clinical variable that predicted cognitive test performance. Closer analysis of the 
data revealed that despite the statistically significant differences in psychological symptoms, 
the group means on the anxiety and depression scales were not clinically significant. Thus, 
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although the neuropsychiatric SLE group reported a greater number of symptoms consistent 
with depression, they were not clinically depressed.  This uncertainty and debate as to 
whether emotional and psychological disturbances in SLE reflect CNS involvement or a 
reaction to a chronic illness has informed research exploring cognitive dysfunction in patients 
testing positive for antiphospholipid antibodies, SLE-related APS and Primary APS.   
 
4.3. APS and Cognitive Dysfunction: The Evidence Base 
 
4.3.1. Cognitive dysfunction, antiphospholipid (aPL) antibodies and Systemic lupus 
erythematosus 
 
Studies of SLE patients with aPL antibodies have shown that the antibodies may play 
a primary role in the pathogenesis of cognitive impairment and that the application of 
neuropsychological assessments has a use in detecting early neuropsychiatric involvement in 
these patients. Maeshima,Yamada, Yukawa and Nomoto (1992) reported that 72% of SLE 
patients (n = 21) with aPL antibodies demonstrated abnormal neuropsychological findings in 
visuoconstructive skills and verbal learning. This study did not include any measures of 
depression or emotional distress. Denburg, Carbotte, Ginsberg and Denburg (1997) revealed a 
significant association between SLE patients testing positive for aPL antibodies and cognitive 
impairment. These patients scored significantly lower than healthy controls (effect size range 
= .52 to 1.24) on most measures and SLE patients that tested negative for aPL antibodies 
(effect size range = .42 to .79) on measures of verbal memory, cognitive flexibility and 
psychomotor speed. Furthermore, aPL positive patients were found to be two to three times 
more impaired than aPL negative patients. There was no significant relationship with 
cognitive impairment and emotional distress. Of note is that subsequent analysis of subjects 
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from this study that did not have neuropsychiatric disease (CNS involvement) produced 
similar results. In another study by Leritz et al. (2002) including aPL antibody patients 
without CNS involvement, aPL positive patients (n=29) performed significantly worse than 
aPL negative patients (n = 27) on measures of neuropsychological functioning including 
attention, concentration, visual search, spatial learning and memory. No clear pattern of 
cognitive impairment emerged. Of importance was the finding that when the influence of 
depression was removed statistically, the aPL positive group still performed worse indicating 
that observed deficits were not necessarily a manifestation of depressive symptoms. This 
study was weakened by considerable attrition rates in both groups, although there were no 
differences between groups (Leritz et al., 2002).   
 
The studies described have relied mainly on one-time assessment and so do not 
consider influence of aPL antibodies as they fluctuate. The relationship between aPL antibody 
levels and neuropsychological functioning has been examined in longitudinal studies by 
several researchers with varying results. Hanly, Hong, Smith and Fisk (1999) classified 
groups of SLE patients with and without CNS involvement as cognitively impaired or 
unimpaired and examined changes on neurological assessment performance in relation to aPL 
status over five years. Patients testing positive for aPL antibodies demonstrated significantly 
greater decline in the areas of conceptual reasoning and executive ability. Those with 
persistently elevated aPL levels performed worse over time on tasks of psychomotor speed.  
Another longitudinal study (Menon, et al., 1999) reported an association between aPL levels 
and cognitive functioning in SLE patients assessed on two occasions separated by 12 to 18 
months. Patients with persistently elevated aPL levels performed more poorly on areas of 
verbal fluency, concentration, attention and reaction time. No significant relationship between 
cognitive functioning and actual antibody level was found. However, the reliability of the 
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study was of concern due to the small sample and the exclusion of any measure for low mood 
or distress. 
 
4.3.2.  Cognitive dysfunction in Primary APS and SLE-related APS 
 
Among studies that have included patients with a diagnosis of definite APS, most have 
focused on dementia or cognitive decline in an aging population but have not provided data 
on the subtle forms of cognitive dysfunction (Gomez-Puerta et al., 2005; Asherson et al., 
1987; Inzelberg, Bornstein, Reider, &  Korczyn, 1992) . Chapman, et al. (2002) identified a 
high frequency of dementia in PAPS patients using a screening tool and standard clinical 
criteria. Fifty six percent of APS patients had dementia based on diagnostic criteria (demented 
APS patients mean age = 68 compared to non-demented APS patients mean age = 51). 
However, standardised cognitive tests were not used.  
 
In studies which have explored the presence of less severe cognitive dysfunction with 
neuropsychological measures, sample sizes have been small. Aharon-Peretz et al. (1995) used 
a comprehensive battery of neuropsychological tests to examine 20 patients with PAPS (14 
with CNS involvement) and 10 healthy controls. Thirteen of the 14 patients with CNS disease 
had mild cognitive deficits. These included: impaired attention, semantic fluency, memory 
and visuospatial functions and slowing of thought process. Aharon-Peretz et al. (1995) did not 
include measures of emotional and or psychological distress and three participants had an 
affective disorder and three met diagnostic criteria for schizophrenia.  Mikdashi and Kay 
(1996) described 4 PAPS patients (without CNS involvement) with impairment in visual 
attention, executive function abilities and impairment in verbal and non verbal-memory skills. 
In an unpublished pilot study comparing 13 PAPS patients with SLE patients with aPL 
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antibodies matched for gender, age, education and IQ, results indicated lower mean scores for 
PAPS patients on ten neuropsychological tests, performance on two of the tests was 
significant (Harrison & Ravdin, 2006).   
 
Tektonidou et al.  (2006) examined patients with PAPS (n = 39), SLE-related APS (n 
= 21), healthy controls (n = 60) and disease controls (n = 25; 15 patients with SLE and 10 
patients with rheumatoid arthritis) using a neuropsychological battery measuring learning and 
memory, attention, executive functions and visuospatial skills and depression. The findings 
indicated that 42% of the 60 patients with APS and SLE-related APS (combined) had 
cognitive deficits compared with 18% of healthy controls (p = .005). Deficits were common 
in verbal fluency and complex attention. There was no difference in cognitive performance 
between PAPS patients and SLE-related APS patients or the disease and healthy controls 
groups. This study used a comprehensive battery of neuropsychological tests and having a 
disease control group strengthened the methodology. However, the small sample size has 
implications for power in detecting modest differences. Mild and severe depression was 
reported in 5% of the APS group (combined); no details of how this was measured were 
given. 
 
Finally, Jacobson, Rapport, Keenan, Coleman and Tietjen (1999) conducted a study 
with subjects without an autoimmune disease, neurological disease (CNS involvement) or 
psychiatric history (including depression) but who tested positive for aPL antibodies. The 
findings demonstrated significant differences from a matched control group on measures of 
memory, executive functioning, verbal learning and visuospatial skills. There were no 
significant associations between cognitive impairment and depression. 
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In summary, there are a limited number of empirical investigations examining the 
cognitive dysfunction in patients with PAPS; most focus on the role of aPL antibodies in 
patients with SLE-related APS. Neuropsychological assessments have been useful in 
identifying cognitive impairment in these populations. The research reviewed reveals that aPL 
antibodies in those with and without an autoimmune disease diagnosis of PAPS or SLE-
related APS, regardless of CNS involvement, are not likely a cause of global cognitive 
dysfunction but that any relationship that exists between these antibodies and cognition is 
complicated. Studies that were methodologically more robust considered moderator variables 
such as psychological and emotional distress and demonstrated that cognitive deficits may not 
always be associated with such factors.   
 
4.4. APS: A Chronic Illness - Quality of Life and Psychosocial Adaptation    
 
4.4.1. Chronic illness and quality of life 
 
APS is a chronic illness meaning it involves a disease of a long-lasting nature without 
a prospect of cure, characterised by a progressive course (de Ridder, 2004).  Being diagnosed 
with a chronic illness has the potential to induce profound changes in a person’s life resulting 
in serious negative effects on quality of life (Dimond, 1984).  Quality of life refers to a broad 
set of concepts such as well-being, satisfaction, happiness and functionality as well as 
financial and environmental factors (de Ridder, 2004). More specifically, in the context of 
chronic illness it considers that individuals may be faced with significant changes in their life 
roles and social and familial relationships while concurrently managing psychological 
distress, physical pain, prolonged medical treatment and interference or restriction in 
activities related to daily living (Charmaz, 1983; Livneh & Antonak, 1997). The way in which 
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people navigate the process of adapting to these life changes from the onset of chronic illness 
has been an important concept in research (Brennan, 2001). 
 
4.4.2. Psychosocial adaptation to chronic illness: psychological models 
 
At a fundamental level, adaptation may be conceived as a process of responding to the 
functional, psychological and social changes that occur with the onset and experience of 
living with a disability and/or chronic illness (Bishop, 2005). Psychological studies on 
adaptation to chronic illness are guided by models of stress and coping, focusing on the role 
of stress and moderators of stress at onset and during the course of illness. These models 
derive from general frameworks regarding adaptation to stressful experiences, highlighting 
the role of stressors as possibly affecting health outcomes, well-being and adjustment (Cohen 
& Lazarus, 1979).  
 
Lazarus and Folkman’s (1984) transactional cognitive-phenomenological theory 
postulates that the impact of stress, such as the diagnosis of a chronic illness, is mediated by 
cognitive appraisals of the illness and the personal and social resources available to assist 
coping with it. Individuals adapt to illness by applying coping strategies that are appropriate 
to the situation. These coping strategies are either problem-focused, to alter person-
environment relationships, which are appropriate when the stressor is deemed changeable and 
emotion-focused coping strategies to regulate internal states, appropriate where the stressor is 
unchangeable.  
 
A later model, proposed by Livneh and Antonak (1997) suggested  that four groups of 
variables influence adaptation outcomes including disability-related variables, 
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sociodemographic factors, personality attributes (locus of control, coping strategies) and 
social and environmental factors. This interactive model is more congruent with the concept 
of psychosocial adaptation being a complex and individual process (Larson & Lubkin, 2009). 
 
A more recent interactive framework related to adaptation includes Moos and 
Holahan’s (2007) conceptual model of the determinants of health related outcomes of chronic 
health and disability. The model conceptualises coping and integrates it into a broader model 
which proposes five sets of factors that are associated with the selection of appropriate coping 
skills and resulting health outcomes such as adaptation. Included are three factors that 
influence cognitive appraisal: 1) personal resources, 2) health-related factors and 3) social and 
physical context. An individual’s cognitive appraisal dictates what adaptation tasks need to be 
accomplished. These adaptation tasks include: managing symptoms, treatment and emotions, 
forming relationships with healthcare providers, maintaining a positive self image, relating to 
family members and friends and preparing for an uncertain future. The three factors 
influencing cognitive appraisal and the cognitive appraisal itself then mediates the choice of 
coping skills leading to the outcome of adaptation. The categories of coping skills identified 
by Moos and Holahan (2007) include: logical analysis and the search for meaning, positive 
reappraisal, seeking guidance and support, taking problem-solving action, cognitive 
avoidance or denial, acceptance and resignation, seeking alternative rewards and emotional 
discharge. 
 
Points of consensus that have emerged across theories include the notions that 
adaptation to the onset of chronic illness is a highly subjective, unique and complex 
multidimensional process, sensitive to the environment and its demands and resources, and to 
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personality traits that influence the appraisal of illness, and the resources for coping (Bishop, 
2005; de Ridder, 2004; Folkman & Moskowitz, 2004).  
 
4.4.3. Quality of life: an indicator of adaptation 
 
Because adaptation is multidimensional, it is suggested that an appropriate measure of 
adaptation to chronic illness is one that a) is sufficiently broad to assess change across a range 
of life domains and b) is able to portray the individual’s subjective experience of changes 
within those domains (Bishop, 2005). As quality of life represents an appropriate framework 
for defining and understanding the adaptation process, quality of life measures are considered 
most likely to tap into broad dimensions of a person’s representations of their physical and 
social world (Brennan, 2001).  
 
4.5. Quality of Life (QoL), Health Related Quality of Life (HRQoL) and Cognitive    
Dysfunction 
 
4.5.1. QoL and HRQoL 
 
Primary outcomes in health care were traditionally focused on mortality and 
morbidity. However, identifying the impact of interventions and describing and characterising 
the patient’s experience of medical care through quality of life (QoL) assessments in health 
settings is now common (McGee, 2004). 
 
Definitions of QoL proliferate ranging from philosophical statements to pragmatic 
definitions, developed to assist operationalising the concept (McGee, 2004). QoL as a concept 
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is regarded as broad and within it are included concepts such as well-being, satisfaction, 
happiness, expectancy, or functionality as well as financial and environmental factors. The 
concept of Health Related Quality of Life (HRQoL) has been adopted to focus primarily on 
medical aspects and has developed from the idea that where health interventions address 
health-related aspects of an individual’s life, they should be evaluated against HRQoL 
parameters. HRQoL as a separate concept from QoL has been defined by Revicki et al. (2000) 
as, “The subjective assessment of the impact of disease and treatment across the physical, 
psychological social and somatic domains of functioning and well-being” (p.888). 
 
Much research exploring quality of life in patients with chronic illness relates to 
HRQoL, referring to quality of life aspects specific to an individual’s health. Physical, social 
and role functioning and mental and general health are included in most conceptualisations of 
HRQoL. Concepts of vitality, pain and neurocognitive functioning are generally subsumed 
under these broader domains (Ware, 1987). The term HRQoL will be adopted hereon in this 
review. 
 
4.5.2. HRQoL in PAPS 
 
No research exploring the illness experience of patients with PAPS through HRQoL 
measures could be found at the time of this review. However, there has been one small scale 
study (N=10) by Erkan, Yazici, Sobel and Lockshin (2000) investigating long-term functional 
outcome (after 10 years) of APS patients experiencing various clinical symptoms of APS. 
Eight patients with organ damage were unable to perform everyday activities important to 
their quality of life (functionally impaired). Causes of functional impairment were cognitive 
dysfunction, cardiovascular disease, aphasia and expressive aphasia. 
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Research that has adopted HRQoL measures with patients with other autoimmune 
diseases such as SLE has been extensive and findings indicate that scores on HRQoL 
measures in this population have been 30-40% lower than those reported by matched peers 
(Sweet, Doninger, Zee, & Wagner, 2004). All domains of HRQoL appear to be affected by 
SLE (Fortin, et al., 1998; Gladman, Urowitz, Ong, Gough, & Mackinnon, 1996; Wang, Mayo, 
& Fortin, 2001) and domains most affected include subscales assessing general health, 
vitality, physical functioning, roles physical and roles emotional. 
 
4.6. Cognitive Dysfunction and HRQoL in PAPS and Other Chronic Illnesses 
 
4.6.1. Cognitive dysfunction and HRQoL in PAPS 
 
Research focussing specifically on the relationship between cognitive functioning and 
HRQoL in patients with PAPS could not be found at the time of this review.  
 
Studies which highlight important considerations for PAPS patients include those with 
other clinical populations such as patients with SLE and patients with neurological conditions.  
 
4.6.2. Cognitive dysfunction and HRQoL in SLE 
 
There is a paucity of studies exploring cognitive dysfunction and HRQoL with SLE 
patients. The most recent and most well described study is that of Tam et al. (2008). This 
included a sample of 291 Chinese SLE patients.  Validated measures were employed to 
ascertain the association of neuropsychiatric manifestations, including cognitive functioning, 
depression and anxiety, and HRQoL. Measures of cognitive functioning were intended to 
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identify impairments in memory and language and executive functioning and included 
Chinese versions of the Mini-Mental State Examination (MMSE) and the Mattis Dementia 
Rating Scale – Initial/Preservation (CDRS-IP) subscale. Anxiety and Depression were 
measured with the Hospital Anxiety and Depressions Scale (HADS) and the Medical 
Outcomes Survey Short Form-36 (SF-36) was used to measure HRQoL. Findings 
demonstrated that cognitive impairments of executive functioning as measured by the CDRS-
IP were associated with impairment of the mental health subscale of the SF-36.  Of note was 
the finding that the HADS depression score was the only independent explanatory variable 
associated with impairment of all subscales of SF-36, which measures both physical and 
mental health functions. The HADS anxiety score was associated with four mental health 
subscales. Anxiety and depression were not significantly associated with any other 
demographic or clinical variables.  
 
Tam et al. (2008) acknowledge that the measures used to identify cognitive 
impairment are not necessarily sensitive enough for more mild cognitive deficits, such as 
those reported in patients with APS. 
 
Hanly, Cassell and Fisk (1997) incorporated a comprehensive battery of 
neuropsychological measures which included the WAIS-R and WMS-R, in a longitudinal 
study exploring cognitive functioning in patients with SLE over a five year period. Patients 
were assessed at three time points. HRQoL was measured with the SF-36 at the final time 
point. No significant differences were found between patients who displayed cognitive 
impairment (n = 7) and those who did not (n = 53).  
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Where occupational status is one objective measure of global functioning that 
correlates with QoL ratings in a variety of medical disorders there are studies that have 
focused on employment (Panopalis et al., 2007; Utset, Fink, & Doninger, 2006). Utset et al. 
(2006) demonstrated the specific influence of cognitive impairment on work status in 50 SLE 
patients.  Patients were assessed for work status, disease characteristics, fatigue, anxiety, 
depressive symptoms, HRQoL and neuropsychological performance. Extensive 
neuropsychological assessments included a range of measures  for pre-morbid verbal IQ,   
verbal and visual memory, attention/processing speed, working memory, language function,. 
motor speed and HRQoL. Fifty percent of patients had cognitive impairment. Of these, 32% 
had obtained formal work disability, 16% had self-report work disability and 52% denied 
having work disability. Subjects with self-reported work disability were more likely to have 
neurocognitive dysfunction and poor quality of life. 
Panopalis et al. (2007) assessed the contribution of memory impairment to 
employment status in 832 patients with SLE.  After adjusting for covariates such as disease 
duration, disease activity, education level, depressive symptoms and demographic variables, 
those with mild-moderately or severely impaired memory experienced greater work disability 
than those with intact memory function. There was also a strong correlation between 
depressive symptoms and memory impairment. Depressive symptoms were found to be a 
strong predictor of employment and inability to work. Even mild memory impairment 
interfered with work as key aspect of quality of life. 
 
4.6.3. Cognitive dysfunction and HRQoL in neurological conditions 
 
Studies in neurological conditions demonstrate that cognitive impairment is a strong 
predictor of quality of life (Mitchell, Kemp, Benito-Leon & Reuber, 2010; Mitchell, Benito-
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Leon, Gonzales & Rivera-Navarro, 2005). Historically, these studies have focused on 
dementia and severe cognitive impairment but recently, there has been an increasing 
recognition of a broad spectrum of impairment including subclinical or mild cognitive 
impairment (Mitchell et al., 2010). Research has revealed that mild impairment with specific 
deficits such as inattention, dysexecutive function and processing speed may influence ability 
to work, interpersonal relationships and leisure activities. This research is summarised below. 
 
Compared with healthy controls, patients with brain tumours demonstrate significant 
reductions in information processing speed, psychomotor function, verbal and working 
memory, executive functioning and HRQoL (Klein et al., 2003). Subtle deficits were found to 
prevent some brain tumour survivors from returning to pre-morbid autonomy and occupations 
(Giovagnoli & Boiardi, 1994).  
 
In stroke patients, Hochstenbach, Anderson, Van Limbeck, & Mulder, (2003) 
employed a comprehensive battery of neuropsychological tests and found HRQoL to be 
associated with deficits in spatio-temporal and or/sequential aspect of behaviour. Poor 
HRQoL was more likely if patients had a poor result on the Trail Making Test B. Kuahanen et 
al. (2000) found that infarct volume, aphasia, impaired motor and cognitive function were 
linked to poorer QoL however, depression was the most significant. 
 
Occupational status is an objective measure of global functioning that also correlates 
with QoL ratings in head injury (Mitchell et al., 2010). Even In mild traumatic brain injury, 
verbal memory, verbal fluency and speed test of planning and strategy are predictive of work 
status 3-15 months later. Many studies with patients with MS demonstrate an association 
between cognitive deficits and lowered HRQoL (Amato, Ponziani, Siracusa, & Sorbi, 2001; 
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Cutajar et al., 2000; Gold, Schulz, Monch, Shulz, & Heesen, 2003; Shawaryn, Schiaffino, 
Larocca, & Johnston, 2002) including memory impairment and executive function and 
information processing. Mitchell et al., 2006 examined all degrees of cognitive impairment 
using a neuropsychological testing as well as the Clock Drawing Test and MMSE screening 
instruments. After controlling for depression, comprehensive ratings of cognition contributed 
to poor HRQoL.  
 
While there have been no studies including patients with PAPS or SLE-related APS, 
overall, there is empirical evidence demonstrating that cognitive dysfunction, from mild to 
severe, in chronic illnesses and neurological conditions is associated with poor HRQoL, even 
when depression is controlled for. The implications on a direct level therefore, are that 
cognitive dysfunction influences physical, psychological and social domains of functioning 
and well-being which may relate to adaptation and coping with illness and disability.  
 
5. FUTURE DIRECTIONS AND IMPLICATIONS 
 
Primary APS is a chronic illness with many clinical features including cognitive 
dysfunction ranging from mild to severe. This review has focused on this clinical 
manifestation because it remains poorly recognised (Gordon, Goldenberg, Erkan, & Lockshin, 
2009; Pattanaik & Brey, 2006), with few studies utilising sensitive neuropsychological 
measures to assess the prevalence and nature of these deficits (Pattanaik & Brey, 2006). 
Although PAPS is the pure form of APS, it is this group about whom the least is known 
(Vincent & Mackworth-Young, 2006). The studies presented in this review have included 
SLE patients testing positive for aPL antibodies as it is this population that closely resembles 
that of PAPS. These studies, therefore, contribute to knowledge and inform future research in 
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this clinical population. The findings demonstrate cognitive deficits in groups with and 
without CNS involvement of the disease in a variety of domains including: attention, semantic 
fluency, memory, visuospatial functions, executive functioning and psychomotor speed. It is 
recognised that some impairments in this population are so mild such that they are not easily 
recognised by measures of cognitive functioning. Furthermore there appears to be no specific 
pattern in the cognitive deficits of this group. These findings suggest the necessity for the 
utilisation of a comprehensive battery of sensitive well validated and reliable 
neuropsychological measures in future studies. Furthermore, while some studies found 
emotional and psychological distress had no association with cognitive dysfunction, the role 
of these variables remains unclear; as such, future research may also control for these 
variables to add further rigour to research design.    
 
In focusing on cognitive dysfunction, this review has highlighted the influence that 
this clinical feature may have on a patient’s HRQoL, an important measure of health 
outcomes. HRQoL relates to the adaptation to functional, psychological and social changes 
experienced by some patients with a diagnosis of a chronic illness. This review has 
demonstrated that there is also a paucity of research investigating HRQoL outcomes with this 
clinical population. Research exploring this multi-dimensional concept in similar chronic 
illnesses has been presented, because, again, it can contribute to our knowledge about quality 
of life as an indicator of adaptation in patients with PAPS and inform the design of future 
empirical investigations with this population. The studies presented highlighted the 
relationship between cognitive deficits and poor HRQoL suggesting that patients may 
struggle to adapt and cope with this clinical feature specifically. As there has been no research 
exploring this experience in PAPS, it is recommended that future studies address this gap in 
knowledge as it may contribute to significantly influencing health outcomes for patients.  
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It is expected that the number of patients with APS and the number recognised as 
having APS will grow (Kasthuri & Roubey, 2009). Therefore a better understanding of the 
nature of cognitive dysfunction in PAPS patients and the influence this has on quality of life 
is theoretically and clinically important in informing the development of treatment 
approaches. There may be a role for health professionals, such as clinical health 
psychologists, to monitor cognitive functioning in this clinical population and to intervene 
where patients are having difficulties adapting to the condition. Advancing the understanding 
of PAPS should facilitate the development of improved treatment and outlook for patients 
with all forms of APS (Vincent & Mackworth-Young, 2006).    
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Abstract 
 
Objective: To explore the relationship between cognitive functioning and health related 
quality of life (HRQoL) in patients with Primary Antiphospholipid Syndrome (PAPS).  
Method: Cross sectional comparisons of PAPS patients (PAPS thrombosis; n = 15; PAPS 
pregnancy; n = 15) and healthy controls (n = 15) on a battery of neuropsychological 
assessments and a measure of HRQoL.  
Results: PAPS thrombosis patients were twice as likely to be designated as cognitively 
impaired compared to PAPS pregnancy patients. PAPS thrombosis patients demonstrated 
lower performance on measures of memory and executive functioning compared to controls. 
PAPS pregnancy patients also performed more poorly on these measures compared to 
controls although not significantly. Both groups demonstrated poor HRQoL across physical 
and mental subscales. Both groups were significantly more impaired in all physical domains 
and one mental domain of HRQoL compared to controls. Neuropsychological outcomes in 
general intellectual abilities, memory and executive functioning were significantly associated 
with mental HRQoL subscales in PAPS thrombosis and executive functioning and memory 
were significantly associated with physical HRQoL subscales in PAPS pregnancy.  
Conclusions: Cognitive impairment is associated with and is more prevalent in PAPS 
thrombosis patients when compared with PAPS pregnancy patients. Both PAPS groups 
demonstrate poor HRQoL which is associated with executive functioning and memory.  
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Introduction 
Overview of APS 
Antiphospholipid syndrome (APS) is an autoimmune disease and is a prothrombotic 
condition defined by the presence of clinical event/s including venous/arterial thrombosis 
and/or pregnancy complications (pre-eclampsia, placental abruption, intra-uterine growth 
restriction) in association with laboratory blood tests confirming moderate-to-high titer 
antiphospholipid (aPL) antibodies and/or the presence of the lupus anticoagulant (Miyakis et 
al., 2006). APS may be primary (primary APS; PAPS) occurring as an isolated diagnosis, or it 
may be associated with other underlying autoimmune disorders. There is a high prevalence of 
APS among patients with Systemic lupus erythematosus (SLE) – also referred to as SLE-
related APS (Tektonidou, Varsou, Kotoulas, Antoniou, & Moutsopoulos, 2006). 
 The clinical spectrum of APS features is extensive (D’Cruz, 2006) and central nervous 
system (CNS) involvement is one of the most common features including major 
neuropsychiatric manifestations such as stroke, seizures, migraine, transient ischaemic attack, 
chorea, psychosis, multiple-sclerosis (MS) like features, sensorineural hearing loss and mood 
disorders. Cognitive dysfunction is also a feature however it remains poorly recognised and 
relatively unexplored (Gordon, Goldenberg, Erkan & Lockshin, 2009; Pattanaik & Brey, 
2006).  
Where APS is characterised by the presence of moderate-to-high aPL antibodies, they 
can be present at low levels with an absence of clinical events and therefore asymptomatic 
patients testing positive for aPL antibodies do exist. However, these patients can experience 
some of the neuropsychiatric syndromes that those with definite APS experience such as 
seizures, chorea, migraine and cognitive dysfunction (Erkan, Kozora & Lockshin, 2011). 
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 Cognitive dysfunction in APS: Overview 
Cognitive deficits associated with APS can vary from mild neurocognitive disorders to 
severe global dysfunction in the context of dementia. Although interest in this area has 
increased in recent years, research is limited and few formal neuropsychological studies have 
been conducted to assess the prevalence and nature of cognitive deficits in patients with APS 
(Pattanaik & Brey, 2006). Studies evaluating neurocognitive deficits have mainly included 
SLE patients testing positive for aPL antibodies. Research distinguishing secondary APS and 
PAPS patients specifically is more limited and mainly anecdotal (Pattanaik & Brey, 2006). 
Findings so far have not identified any consistent pattern of cognitive dysfunction.  
 
Cognitive dysfunction, antiphospholipid (aPL) antibodies and Systemic lupus erythematosus 
Studies of SLE patients with aPL antibodies have shown that the antibodies may play 
a primary role in the pathogenesis of cognitive impairment and that the application of 
neuropsychological assessments has a use in detecting early neuropsychiatric involvement in 
these patients. Maeshima, Yamada, Yukawa and Nomoto (1992) reported that 72% of SLE 
patients (n = 21) with aPL antibodies demonstrated abnormal neuropsychological findings in 
visuoconstructive skills and verbal learning. Denburg, Carbotte, Ginsburg and Denburg 
(1997) revealed a significant association between SLE patients testing positive for aPL 
antibodies and cognitive impairment. These patients scored significantly lower than healthy 
controls (effect size range = .52 to 1.24) on most measures and SLE patients that tested 
negative for aPL antibodies (effect size range = .42 to .79) on measures of verbal memory, 
cognitive flexibility and psychomotor speed. Subsequent analysis of subjects from this study 
that did not have CNS involvement produced similar results.  Leritz et al. (2002) found that 
aPL positive patients without CNS involvement (n = 29) performed significantly worse than 
aPL negative patients without CNS involvement (n = 27) on measures of neuropsychological 
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functioning including attention, concentration, visual search, spatial learning and memory. No 
clear pattern of cognitive impairment emerged. When the influence of depression was 
removed statistically, the aPL positive group still performed worse. 
 
Cognitive dysfunction in Primary APS and SLE-related APS 
Among studies that have included patients with a diagnosis of definite APS, most have 
focused on dementia or cognitive decline in an aging population (Gomez-Puerta et al., 2005). 
In studies which have explored the presence of less severe cognitive dysfunction, sample sizes 
have been small. Aharon-Peretz et al. (1995) investigated 20 patients with PAPS (14 with 
CNS involvement) and 10 healthy controls. Thirteen of the 14 patients with CNS disease had 
mild cognitive deficits across a number domains including; attention, semantic fluency, 
memory (working and visuospatial) and executive function (visuomotor and mental 
flexibility). Aharon-Peretz et al. (1995) did not include measures of emotional and or 
psychological distress. Mikdashi and Kay (1996) described 4 PAPS patients (without CNS 
involvement) with impairment in visual attention, executive function abilities and impairment 
in verbal and non verbal-memory skills.  
Tektonidou et al.  (2006) examined patients with PAPS (n = 39), SLE-related APS (n 
= 21), healthy controls (n = 60) and disease controls (n = 25). Forty two percent of the 60 
patients with PAPS and SLE-related APS (combined) had cognitive deficits compared with 
18% of healthy controls (p = .005). Deficits were common in verbal fluency, attention and 
scanning and visuomotor functions. Significant differences were found between all APS 
patients and all controls.   
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Cognitive dysfunction and HRQoL  
As an autoimmune disease, APS is a chronic illness and patients live with the 
condition without a prospect of cure (de Ridder, 2004).  The range of clinical features of APS, 
including cognitive dysfunction, are likely to impact upon aspects of patients’ quality of life, 
where they may be presented with changes in their life roles and social and familial 
relationships while they concurrently manage psychological distress, physical pain, ongoing 
medical treatment and restrictions in the activities of daily living (Charmaz, 1983; Livneh & 
Antonak, 1997).  Studies assessing patients’ processes of adjusting to these changes have 
been informed by models of stress and coping which propose a complex and individual 
process with many physical, psychological, social and somatic factors (Lazarus & Folkman; 
1984; Livneh & Antonak, 1997; Moos & Holahan, 2007).  Research in patients with 
neurological conditions has utilised measures of Health Related Quality of Life (HRQoL) to 
tap into these broad dimensions as a way of measuring the influence of cognitive dysfunction 
on quality of life. Associations between cognitive impairment and poor HRQoL has been 
found in stroke patients (Hochstenbach, Anderson, Van Limbeck, & Mulder, 2001), patients 
with MS, (Amato, Ponziani, Siracusa, & Sorbi, 2001; Cutajar et al., 2000), brain tumours 
(Klein et al., 2003) and traumatic brain injury (Mitchell et al., 2010).  
 
Cognitive dysfunction and HRQoL in PAPS  
Research exploring the relationship between cognitive dysfunction in PAPS and the 
experience of illness and adjustment using HRQoL measures could not be found at the time of 
this study. As research with SLE patients highlights significant factors for PAPS patients it is 
useful to consider findings of research exploring HRQoL in this clinical population. Studies 
indicate that scores on HRQoL measures have been 30 - 40% lower than those reported by 
matched peers (Sweet, Doninger, Zee, & Wagner, 2004) with all domains of HRQoL affected 
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by SLE (Fortin, et al., 1998; Wang, Mayo, & Fortin, 2001). Studies exploring cognitive 
dysfunction in relation to HRQoL in SLE are scarce.  The most recent is that of Tam et al. 
(2008) which investigated the association of neuropsychiatric manifestations, including 
cognitive functioning, depression and anxiety and HRQoL in 291 Chinese SLE patients. 
Findings demonstrated that cognitive impairments of executive functioning were associated 
with impairment on the mental health subscale of a HRQoL measure. 
Where occupational status is one objective measure of global functioning that 
correlates with QoL ratings in a variety of medical disorders, there are studies that have 
explored this specifically (Panopalis et al., 2007; Utset, Fink, & Doninger, 2006). Utset et al. 
(2006) demonstrated the influence of cognitive impairment on work status in 50 SLE patients.  
Fifty percent of patients had cognitive impairment; the 16% that had self report work 
disability were more likely to have neurocognitive dysfunction and poor quality of life. 
Panopalis et al. (2007) assessed the contribution of memory impairment to employment status 
in 832 patients with SLE. Those with mild-moderately or severely impaired verbal memory 
experienced greater work disability than those with intact memory function. Even mild 
memory impairment interfered with work as key aspect of quality of life. 
 
Summary 
Primary APS is a chronic illness with many clinical features including cognitive 
dysfunction ranging from mild to severe. However, cognitive dysfunction remains poorly 
recognised (Gordon, et al., 2009). As the population that most closely resembles PAPS 
includes SLE patients testing positive for aPL antibodies, it is research in this population that 
contributes to knowledge and can inform research in PAPS. Of the few studies with this 
population and APS patients, findings demonstrate cognitive deficits in groups with and 
without overt CNS involvement in a variety of domains. However, there appears to be no 
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specific pattern of cognitive impairment nor is there clarity about the role of physical, 
psychological, social and somatic experiences and their association with cognitive deficits in 
these clinical groups.   
 It is expected that the number of patients with APS and the number recognised as 
having APS will grow (Kasthuri & Roubey, 2009). Therefore a better understanding of the 
nature of cognitive dysfunction in PAPS and the influence it has on quality of life is 
theoretically and clinically important in informing the development of treatment approaches. 
This study aims to address this, utilising sensitive well validated and reliable HRQoL and 
neuropsychological measures to examine the relationship between cognitive functioning and 
quality of life in patients with PAPS. Further aims of this study are to establish the 
characteristics and prevalence of cognitive dysfunction and HRQoL in PAPS. It is 
hypothesised that PAPS patients will demonstrate i) impaired cognitive functioning on all 
neuropsychological measures and ii) impaired HRQoL in all domains of the HRQoL measure 
and that iii) cognitive functioning will be positively correlated with HRQoL. 
 
 
Method 
Study design and participants 
 In this cross-sectional study, performance on measures of cognitive function and 
HRQoL were compared in patients with PAPS and healthy controls. Participants included 30 
female patients with definite PAPS - diagnosed according to the Sydney Criteria (Miyakis et 
al., 2006). Patients were divided between those who had experienced vascular thrombosis (n = 
15; PAPS thrombosis) and those who had experienced pregnancy complications (n = 15; 
PAPS pregnancy). Patients were recruited from a large London medical centre between 
September 2010 and May 2011. The control group (n = 15) consisted of a convenience 
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sample of healthy volunteers personally known to the researcher and research assistants. The 
volunteers were recruited from the London, the South West and South East of the United 
Kingdom.  
 
Exclusion criteria 
As PAPS defined by pregnancy complications includes females only, and in order for 
the groups to be as closely matched as possible, the vascular thrombosis and healthy control 
groups excluded males. To ensure any cognitive and psychosocial problems identified in this 
study relate to PAPS it was important to exclude individuals with a medical or psychiatric 
history and/or major neuropsychiatric manifestations (stroke, transient ischemic attacks, 
chorea and demyelinating disorders) that might otherwise account for their symptoms. 
Participants were excluded if they were pregnant or lactating; had experienced a very recent 
(≤ 3 months) thrombotic event or pregnancy loss; had a diagnosis of SLE, any other definite 
autoimmune connective tissue disorder (one participant had Rheumatoid Arthritis), 
fibromyalgia, chronic fatigue syndrome or chronic viral infections (such as HIV, Hepatitis B 
or C); were using anti-psychotic or anti-depressant medication or had a known history of drug 
misuse.  Individuals who were non-English speaking were also excluded due to the nature of 
measures utilised in this study. 
 
Power analysis 
Power calculations were made using the Gpower software package (Erdfelder, Faul & 
Buchner, 1996). For significant univariate analysis of variance (ANOVA) at a 0.05 level of 
significance, a power of 0.80 and a medium effect size (Cohen, 1969; d = 0.5), 42 participants 
in total are required. For significant Pearson’s product-moment correlations at a .05 level of 
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significance, a power of 0.80 and medium effect size (Cohen, 1969; r = 0.4), 37 participants 
in total are required. 
 
Procedure 
Potential participants were identified by consultants and a research nurse when they 
attended their hospital clinic appointment. They were provided with written and verbal 
information about the study. If they agreed to take part, their contact details were given to the 
researcher so that an appointment could be made at a mutually convenient time to complete 
the measures.  
 Participants in the clinical groups met with the researcher or a research worker 
(assistant psychologists) at the hospital for 2.5 hours to complete a battery of 
neuropsychological assessments and questionnaires measuring HRQoL and mood. Those 
administering the assessments were not aware of the participant’s medical status and were 
therefore blind to which group they were in. Two participants could not attend the hospital to 
participate (one due to anxiety relating to travelling by public transport and one due to 
difficulties with childcare arrangements) - they were visited in their homes to undergo the 
assessments. Participants in the healthy control group were visited at their home or at their 
place of work to complete the assessments.  
 
Ethical approval 
Ethical approval for this study was granted by the National Health Service (NHS) 
Research Ethics Committee (Appendix B) and NHS Research and Development for the 
participating trust (Appendix C). All participants were informed about the nature and purpose 
of the study and of the way data would be handled. This information was provided by the 
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research nurse, the researchers and on an information sheet (Appendix F). Written informed 
consent was obtained by all those who took part. 
 
Measures of neuropsychological function 
A psychometric battery of tests to cover a range of cognitive functions was 
administered comprising measures that are routinely used in clinical practice within the NHS. 
All tests have adequate published reliability, validity and normative data and included: 
The Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999; Appendix S) 
is an abbreviated version of the full battery of intellectual functioning measure, the Wechsler 
Adult Intelligence Scale III (WAIS III; Wechsler, 1998). It is standardised on the U.S 
population and comprises four subtests that measure verbal, non-verbal and general cognitive 
functions. Raw scores for each subtest are converted to standardised scores. The Vocabulary 
subtest, which assesses expressive vocabulary and verbal knowledge and the Similarities 
subtest, which measures verbal concept formation and abstract reasoning ability, form the 
Verbal Scale and yield a Verbal IQ score (VIQ). The Block design subtest, which assesses 
spatial visualisations, visual motor coordination and abstract conceptualisation and the Matrix 
Reasoning subtest, which assesses nonverbal fluid reasoning and general intellectual ability, 
form the Performance Scale and yield the Performance IQ (PIQ). The four subtests comprise 
the full scale and yield the Full Scale Intellectual Quotient (IQ; FSIQ). Reliability coefficients 
represent a high level of internal consistency with ranges as follows: Vocabulary, 0.90 to 
0.98; Similarities, 0.84 to 0.96; Block Design, 0.90 to 0.94; Matrix Reasoning, 0.88 to 0.96.  
The reliability coefficients for the scale scores ranged from 0.92 to 0.98 for VIQ and 0.94 to 
0.97 for PIQ. The reliability coefficients for Full Scale IQ scores ranged from 0.96 to 0.98 for 
the full FSIQ-4 (Garland, 2005). The similarity between the items in the WASI and the 
parallel items in the WAIS III ensure that the content validity is maintained (Garland, 2005).  
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 Wechsler Adult Intelligence Scale III (WAIS III UK; Wechsler, 1998) 
The WAIS IIIUK is a full battery of psychometric intelligence assessments also standardised 
on the US population but with small modifications to create a UK version (Wechsler, 1998). 
It contains fourteen subtests each measuring different facets of intelligence. The subtests 
include four subtests of the WASI (see above) as well as Information, Picture Completion, 
Arithmetic, Digit Span, Letter-Number Sequencing, Digit Symbol Coding and Symbol 
Search. Raw scores for each test are converted to standardised scores. The WAIS III also 
yields the three composite scores; VIQ, PIQ and FSIQ. Three subtests were used from the 
WAIS IIIUK including: Digit Span, to measure information processing and complex attention, 
Digit Symbol Coding, to measure visual motor co-ordination and processing speed and 
Symbol Search, to measure visual perception and motor speed (Appendix T). Average 
reliability coefficients for these subtests were .90, .84 and .77 respectively. The subtests for 
the WAIS III are reported to have good content and construct validity (Silva, 2008). 
 The National Adult Reading Test (NART; Nelson, 1982) is a test with good reliability 
(reliability coefficient 0.93) and validity (Crawford, Dreary, Starr & Whalley, 2001) 
commonly used to estimate pre-morbid intellectual functioning (Appendix U). It is a 50 single 
item word reading test of graded difficulty. The examinee reads each word aloud and the 
number of errors made is recorded. WAIS VIQs, PIQs and FSIQs can be predicted from the 
reading error score.  The NART was standardised on a series of 120 patients between the ages 
of 20 and 70 with extra-cerebral disorders, mainly spinal cord disorders and neuropathies. 
Research indicates that NART performance is not greatly influenced by the effects of many 
neurological and psychiatric disorders, as judged by the absence of significant differences 
between the clinical and control samples.  
 Delis Kaplan Executive Function System (DKEFS, Delis, Kaplan, & Kramer, 2001) is 
a set of standardised tests consisting of nine subtests that measure a wide spectrum of verbal 
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and non-verbal executive functions. The tests include: Trail Making Test, Verbal Fluency 
Test, Design Fluency Test, Colour-Word Inference Test, Scoring Test, Twenty Questions 
Test, Word Context Test, Tower Test and Proverb Test. Each test is designed to be used either 
as a stand alone test or along with other DKEFs tests. Raw scores for each test are converted 
to standardised scores. The DKEFS standardisation sample consisted of 1,750 children, 
adolescents and adults aged 8 to 89 years (Delis, Kaplan, & Kramer, 2001), selected to match 
the demographic characteristics of the US population.   
 Two subtests were administered; the Verbal Fluency Test (reliability coefficient range 
0.53 to 0.65) which consists of three conditions and assesses the ability to generate words 
fluently in an effortful, phonemic format (letter fluency test), from overlearned concepts 
(category fluency test) and simultaneously shifting between overlearned concepts (category 
switching test) (Appendix V). The test uses the number of words given in each task within a 
time period of 60 seconds to generate a scaled score. The Trail Making Test (reliability 
coefficient range 0.20 to 0.82) which measures cognitive flexibility on a visual motor task 
(Appendix W) was also administered. This test consists of five conditions which assess visual 
scanning, number sequencing, letter sequencing, letter-number switching and motor speed. 
The primary executive function measured by the test is cognitive flexibility in the fourth 
condition (letter-number switching; Delis et al., 2001).  Conditions one, two, three and five 
provide baseline information about component skills to factor out their influence in the 
executive function domain assessed in condition four. This test uses time to complete each 
task to generate a scaled score (Delis et al., 2001).  
 The Brain Injury and Rehabilitation Trust (BIRT) Memory and Information 
Processing Battery (BMIPB) (Coughlan, Oddy, & Crawford, 2007) assesses memory and 
information processing skills. There are four versions (Forms 1, 2, 3 and 4) allowing for 
assessments to be repeated without the problem of content specific practice effects. The test 
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comprises three verbal memory tasks (Story Recall, List Learning and List Recognition), 
three visual memory tasks (Figure Recall, Design Learning and Design Recognition) and an 
information processing task (Number Cancellation). Two of the tests were administered, 
Story Recall (Form 1; Appendix Y) and Figure Recall (Form 1; Appendix Z). In the Story 
Recall task, examinees are read a story and asked to recall it immediately and then again 40 
minutes later. For Figure Recall, examinees copy a complex 2D figure and then are asked to 
reproduce it from memory immediately and then 40 minutes later. Scores for the tests are 
norm based, calculated by a BMIPB computer program providing regression based norms 
using age and education level as predictors.  Normative data for the BMIPB were obtained 
from 300 participants within the UK population within the age range 16-89. The sample 
recruited was intended to reflect as closely as possible the distribution of age, educational 
level and gender within the general population.  
 Camden Memory Tests (CMT; Warrington, 1996) include a standardised battery of 
five tests of different aspects of memory and learning. The tests include the Pictorial Memory 
Test, the Topographical Recognition Memory Test, the Paired Associate Learning Test, the 
Short Recognition Memory Test for Words (CSRMT-W) and the Short Recognition Memory 
Test for Faces (CSRMT-F). Both the CSRMT-W and CSRMT-F (Appendix Z1) are visual 
memory tests and were administered in this study to assess material specific memory deficits. 
The tests require forced-choice recognition of faces and words. The stimuli consist of 25 
stimulus words and faces. In the recognition test, words/faces are paired with 25 distractor 
words/faces. The tests were standardised on adults aged 18-85 educated in the school system. 
Raw scores can be converted to percentile scores for three age groups 18-49, 50-69 and 70-
85. Percentile scores were converted to scaled scores for this study.   
 The Graded Naming Test (GNT; McKenna & Warrington, 1983) is a validated verbal 
fluency test measure which assesses object-naming ability (McKenna & Warrington, 1983; 
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Appendix Z2). The test involves the oral naming of 30 pictures of objects, scoring reflects this 
and so raw scores range from 0 to 30. The 100 people of ‘average’ intelligence in the 
standardisation sample with an age range of 18 to 77 had a mean score of 20.4 (SD = 4.1) 
(Lezak, 2004). Raw scores can be converted to scaled scores based on those of the WAIS 
vocabulary subtest; this converts to a scaled score of 11. The GNT is graded in difficulty to 
allow for individual differences and is therefore able to detect word-finding difficulty even in 
those with an extensive naming vocabulary. The GNT demonstrates good reliability and 
(0.92) has been found to be sensitive to even small cognitive changes (Bird, Papadopoulou, 
Ricciardelli, Rossor, & Cipolotti, 2004).  
 
Measure of HRQoL 
 The Medical Outcomes Survey Short Form-36 (SF-36; Ware & Sherbourne, 1992) was 
used to measure HRQoL (Appendix Z3). This is a 36-item inventory (Stewart, Hays & Ware, 
1988) and is a widely used generic measure of HRQoL across a variety of clinical 
populations. The measure generates 8 subscales: 1) physical functioning, 2) role limitations 
due to physical problems, 3) bodily pain, 4) general health perceptions, 5) vitality, 6) social 
functioning, 7) role limitations due to emotional problems and 8) mental health. These scales, 
weighted according to normative data are scored from 0 – 100 and are T scores (mean = 45 
standard deviation = 10). For group level data T scores of 47 are considered ‘average’. Scores 
higher than 47 therefore reflect better HRQOL and T scores less than 47 indicate impaired 
functioning or well-being. Algorithms were developed by the originators of the SF-36 to 
calculate 2 psychometrically based summary scores: the physical component summary (PCS; 
subscales 1-4 above) and mental health component summary (MCS; subscales 5-8 above) 
(internal consistency reliability estimates of 0.95 and 0.93 respectively; Ware et al., 2007). 
The PCS and MCS provide greater precision, reduce the need for statistical comparisons 
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needed and eliminate the floor and ceiling effects in several of the subscales (Ruta, Hurst, 
Kind, Hunter, & Stubbings, 1998). There is evidence for reliability and validity of the SF-36 
in SLE populations (Panapalis & Clark, 2006).  
 
Measure to screen for depression 
 The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) 
(Appendix Z4) was designed to measure mood disorders in populations with physical illness. 
It consists of 14 items which are scored between 0 and 3 and summed to provide two scores: 
one for anxiety and one for depression. Scores of 11 or higher indicate probable depression 
and are divided into four ranges: normal (0-7) mild (8-10), moderate (11-15) and severe (16-
21).  For the purposes of this study, the HADS was used as a screening tool to assess 
depression. The HADS has demonstrated good validity and reliability and has been widely 
used in research (Bjelland, Dahl, Haug, & Neckelmann, 2002).  
 
Administration of measures and management of data 
All measures were administered by either the researcher or research workers who were 
all experienced in administering these assessments. Further training was also completed prior 
to the research commencing to ensure tests would be administered consistently. The order in 
which assessments were administered was as follows: HADS, SF-36, NART,  BIRT Story 
and Figure - Immediate Recall, WASI, BIRT Story and Figure - Delayed Recall, WAIS 
subtests (digit symbol coding, digit span, symbol search), Camden Memory Battery subtests 
(visual and verbal), Graded Naming Test. The researcher assessed twenty-two of the forty-
five participants. All data were scored and subsequently managed by the researcher. 
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Data analysis  
To have a direct comparison between tests, raw scores from the neuropsychological 
tests were transformed into scaled scores. All variables were assessed for assumptions of 
normality and homogeneity of variance using the Kolmogorov-Smirnov test and Levene’s test 
respectively. Some data significantly violated these assumptions. In group comparisons of 
neuropsychological outcomes and HRQoL, one-way ANOVA and Bonferroni’s post hoc tests 
and Kruskal-Wallis and Mann-Whitney U non-parametric tests were used as appropriate. 
Because of the multiple comparisons, the Bonferroni significance threshold was set at p = 
0.025 for post hoc comparisons. Results were expressed as mean (M) and standard deviation 
(SD) for normally distributed data. Data that violated assumptions was expressed as median 
(mdn) and range. Wilcoxon signed-ranks test was used to compare pre-morbid and current 
levels of intellectual ability in PAPS patients. A criterion for cognitive impairment was a 
score in the pathologic range (i.e. performance below the 5th centile of the normal population) 
in two or more tests (Monastero et al., 2001). The number of patients fulfilling this criterion 
in each group was compared by means of a contingency table (chi-square statistics).  
Spearman’s rho and Pearson’s correlation coefficient were used to examine 
correlations between neuropsychological outcomes and HRQoL scores. The possible effect on 
HRQoL was assessed further by multiple regression analysis (forced entry) where there were 
two or more significant positive correlations between neuropsychological measures and 
HRQoL scores. Comparisons between the three groups, Controls, PAPS pregnancy and PAPS 
thrombosis, for demographic and clinical characteristics were performed using descriptive 
statistics, parametric tests (one-way ANOVA) and non-parametric tests (Kruskal-Wallis). 
Analyses were performed using SPSS for Windows, version 17.0. 
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Results 
Demographic and clinical characteristics 
Demographic and clinical characteristics appear in Table 1. Thirty female patients and 
15 healthy controls were recruited; there were no significant differences in age, education and 
pre-morbid IQ. The median scores for depression on the HADS fell within the ‘normal’ range 
indicating that participants were not depressed. There was, however, a significant difference 
between scores H(2) = 7.08, p<.05.    
 
Table 1 Demographic and clinical characteristics of PAPS patients and healthy controls 
 
  
Control  
(n=15)  
Median (range) 
PAPS Pregnancy 
(n=15) 
 Median (range) 
PAPS Thrombosis 
(n=15)  
Median (range) 
Age  49.00 (23-57)  40.00 (29-47)  46.00 (30-50)  
Years of Education 17.00 (11-19) 17.00 (14-19) 14.00 (12.00-19.00) 
Pre-morbid IQ (NART) 118 (100-125) 114 (100-125) 119 (89-122) 
HADS Depression Score* 1.00 (0-12) 4.00 (1-12) 5.00 (1-15) 
*<.05   
 
Neuropsychological assessment 
Intergroup comparisons indicate that patients with PAPS thrombosis and PAPS 
pregnancy demonstrated lower scores than control subjects (Table 2). Kruskal Wallis tests 
revealed significant differences for four neuropsychological outcomes: WAIS Symbol Search, 
H (2) = 7.50, p < .05, Trail Making 1, H(2) = 6.41, p < .05, Trail Making 5 H(2) = 6.97, p < 
.05 and CSRMT-F, H(2) = 11.09, p < .01. Mann Whitney tests were used to follow up this 
finding. A Bonferroni correction was applied so all effects are reported at a .025 level of 
significance. Effect sizes (r) for significant findings ranged from 0.42 to 0.54. PAPS 
thrombosis patients performed at a significantly lower level than controls on each of the four 
tests: WAIS Symbol Search (U = 57.5, r = -.42); Trail Making 1 (U = 56.5, r = -.43), Trail 
Making 5 (U = 56.0, r = -.43) and CSRMT-F (U = -.54, r = -.54). There were no significant 
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differences between PAPS pregnancy patients and controls on these neuropsychological 
outcomes. 
 Comparisons between estimated pre-morbid IQ (NART) and current IQ (WASI FSIQ) 
were made using Wilcoxon signed-rank test. There had been a significant reduction between 
PAPS thrombosis group’s estimated pre -morbid IQ (mdn = 119) and their current level of 
general intellectual ability (mdn = 109), Z= -2.29, p < .05, r = 0.6. Based on the decline 
between estimated pre-morbid IQ and current IQ, intellectual ability appeared to have reduced 
in PAPS pregnancy patients; the change was not significant. 
  56 
 
 
Data of prevalence of cognitive impairment between the PAPS groups can be seen in 
Table 3. PAPS thrombosis patients demonstrated greater impairment in domains of general 
intelligence; both groups demonstrated impairment in domains of executive functioning and 
memory. Twenty percent of patients in both groups showed impairment on the primary 
Table 2 Analysis of Variance (ANOVA) and non-parametric tests comparing Controls and PAPS 
groups on neuropsychological outcomes 
 
Cognitive Domain/ 
Neuropsychological outcomes 
Control      
(n=15)         
Mean (SD) / 
Median (Range) 
PAPS Pregnancy 
(n=15)            
Mean (SD) / 
Median (Range) 
PAPS 
Thrombosis 
(n=15)            
Mean (SD) / 
Median (Range) 
Test F value/    H value 
General Intelligence      
WASI Vocabulary  11.93 (3.32) 11.20 (2.90) 11.53 (3.70) A 0.18 
WASI Similarities  11.53 (2.41) 11.40 (2.19) 11.13 (2.41) A 0.11 
WASI Block Design  11.40 (2.09) 12.00 (2.36) 10.60 (2.99) A 1.17 
WASI Matrix Reasoning  12.93 (1.98) 12.40 (2.02) 12.20 (1.89) A 0.56 
WASI Verbal IQ 109.13 (14.4) 106.47 (12.3) 107.07 (15.00) A 0.15 
WASI Performance IQ 111.87 (10.87) 111.73 (10.30) 108.07 (12.45) A 0.55 
WASI Full-scale IQ 111.73 (12.59) 110.13 (9.1) 108.33 (10.49) A 0.37 
Executive Functioning      
WAIS Digit Symbol Coding 10.60 (2.53) 10.00 (1.41) 8.67 (2.99) A 2.54 
WAIS Digit Span 11.60 (2.38) 10.40 (2.61) 11.07 (3.17) A 0.72 
WAIS Symbol Search 12.00 (9-18) 12.00 (9-15) 10.00 (4-15) K-W 7.50* 
DKEFS Letter Fluency 12.13 (3.46) 11.53 (2.69) 11.00 (4.01) A 0.41 
DKEFS Category Fluency 13.07 (3.30) 12.07 (3.61) 11.40 (2.94) A 0.97 
DKEFS Category Switching Responses 12.93 (3.90) 11.13 (2.87) 11.27 (4.52) A 1.03 
DKEFS Category Switching Accuracy 12.13 (4.82) 11.53 (2.41) 11.73 (3.97) A 0.09 
DKEFS Trail Making 1 11.00 (8-13) 10.00 (5-13) 10.00 (1-12) K-W 6.41* 
DKEFS Trail Making 2 11.00 (8-13) 10.00 (4-12) 8.00 (1-15) K-W 5.86 
DKEFS Trail Making 3 12.00 (6-15) 11.00 (6-12) 10.00 (11-15) K-W 4.95 
DKEFS Trail Making 4 11.00 (6-16) 10.00 (1-12) 10.00 (1-13) K-W 4.48 
DKEFS Trail Making 5 10.00 (5-12) 10.00 (7-13) 7.00 (2-12) K-W 6.97* 
DKEFS Trail Making Composite Score 12.00 (7-16) 12.00 (15-18) 10.00 (5-16) K-W 5.73 
Memory      
Camden Memory Test Faces 12.80 (10-13) 13.00 (8-13) 12.00 (6-13) K-W 11.09** 
Camden Memory Test Words 13.00 (10-13) 13.00 (8-13) 13.00 (1-13) K-W 1.65 
BIRT Story Recall Immediate 8.47 (3.58) 8.20 (3.23) 8.33 (2.79) A 0.26 
BIRT Story Recall Delayed 9.53 (3.39) 8.93 (3.30) 9.27 (2.65) A 0.14 
BIRT Figure Recall Immediate 9.74 (4.48) 9.64 (2.79) 8.20 (3.38) A 0.841 
BIRT Figure Recall Delayed 9.00 (3.02) 10.21 (2.25) 8.80 (2.21) A 1.32 
Graded Naming 13.00 (9-15) 12.00 (9-15) 13.00 (7-15) K-W 0.81 
*** <.000; ** < .01; * <.05      
A = ANOVA, K-W = Kruskal-Wallis 
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measure of executive functioning (Trail Making 4) and verbal logical memory (BIRT Story 
Recall Immediate). Furthermore, 26.7% of PAPS pregnancy patients were impaired on a 
measure of delayed memory (BIRT Story Recall Delayed). The PAPS thrombosis group 
(6.7%) also showed poor functioning in 3 of the 4 WASI IQ subtests (verbal subtests and one 
performance subtest). Cognitive impairment was identified in four out of 15 (26.7%) in PAPS 
pregnancy patients and eight out of 15 (53.3%) in PAPS thrombosis patients as measured by 
abnormal performance in two or more tests (p = .264, two tailed Fisher’s exact test). 
 
Table  3 Prevalence of cognitive impairment in PAPS Pregnancy and PAPS Thrombosis subjectsa 
 
Cognitive Domain/ Neuropsychological 
outcomes 
PAPS Pregnancy (n=15) 
   n ( %) 
PAPS Thrombosis (n=15) 
   n ( %) p 
b
 
General Intelligence    
WASI Vocabulary  - 1(6.7) ns 
WASI Similarities  - 1 (6.7) ns 
WASI Block Design  - 1 (6.7) ns 
WASI Matrix Reasoning  - - - 
Executive Functioning    
WAIS Digit Symbol Coding - 2 (13.3) ns 
WAIS Digit Span - - - 
WAIS Symbol Search - 1 (6.7) ns 
DKEFS Letter Fluency - - - 
DKEFS Category Fluency 1 (6.7) 1 (6.7) ns 
DKEFS Category Switching Responses - 1 (6.7) ns 
DKEFS Category Switching Accuracy - 1 (6.7) ns 
DKEFS Trail Making 1 1 (6.7) 2 (13.3) ns 
DKEFS Trail Making 2 - 3 (20) ns 
DKEFS Trail Making 3 - 1 (6.7) ns 
DKEFS Trail Making 4 3 (20) 3 (20) ns 
DKEFS Trail Making 5 - 2 (13.3) ns 
Memory    
Camden Memory Test Faces - - ns 
Camden Memory Test Words - 1 (6.7) ns 
BIRT Story Recall Immediate 3 (20) 3 (20) ns 
BIRT Story Recall Delayed 4 (26.7) 1 (6.7) ns 
BIRT Figure Recall Immediate * 1 (7.1) 3 (20) ns 
BIRT Figure Recall Delayed * - 1 (6.7) ns 
Graded Naming - -  
   
* n=14 in both groups     
a Number/percentage of patients impaired 
 
b
 Not Significant after Fisher's Exact test)  
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HRQoL 
The scores for HRQoL, including all eight subscales and the PCS and MCS scores 
were significantly lower in PAPS thrombosis patients and PAPS pregnancy patients compared 
with controls (Table 4). The PAPS pregnancy patients had a lower Bodily Pain score (Mdn = 
50) compared with both PAPS thrombosis (Mdn = 51.13) and controls (Mdn = 62.12). Median 
scores were below 47 on six of the SF-36 subscales and the PCS and MCS for PAPS 
thrombosis patients and median scores on five subscales and the MCS were below 47 for 
PAPS pregnancy patients indicating impaired quality of life.  
 
Kruskal-Wallis tests showed there was a significant difference on five HRQoL 
subscales including Physical Functioning, H(2) = 9.17 p< .01; Role Physical, H(2) = 19.92, 
p< .000; Bodily Pain, H (2) = 9.22, p < .01; General Health, H (2) = 18.70, p< .000 and 
Vitality, F (2, 12) = 6.92, p < .01, ω2 = 1.9 (ω2= omega squared effect size). Mann Whitney 
tests and Bonferroni’s test were used to follow up these findings. A Bonferroni correction was 
Table 4 Analysis of Variance (ANOVA) and non-parametric tests comparing Controls and 
PAPS groups on SF-36 subscales 
 
SF-36 Subscales 
Control       
(n=15)        
 Mean (SD) / 
Median (Range) 
PAPS Pregnancy 
(n=15)            
Mean (SD) / 
Median (Range) 
PAPS 
Thrombosis 
(n=15)            
Mean (SD) /  
Median (Range) 
Test F value/    H value 
SF-36  Physical Functioning 57.03 (47-57) 52.82 (15-57) 42.30a (21-57) K-W 9.16** 
SF-36 Role Physical  56.85 (37-57) 49.51 (20-57) 37.26a (18-57) K-W 19.92*** 
SF-36 Bodily Pain 62.12 (37-62) 50.29 (20-62) 51.13 (29-62) K-W 9.22** 
SG-36 General Health 55.32 (46-64) 43.40a (19-55)  28.15a (19-55) K-W 18.69*** 
SF-36 Vitality 53.54 (8.24) 43.13a (11.18) 40.22a (11.20) A 6.92** 
SF-36 Social Functioning 56.85 (30-57) 40.49a (13-57) 35.03a (24-57) K-W 9.94 
SF-36 Role Emotional 51.99 (21-56) 48.10 (33-56) 48.10 (13-56) K-W 1.88 
SF-36 Mental Health 48.69 (8.37) 45.46a (8.88) 44.56a (8.80) A 0.93 
SF-36 Physical Component Score 58.38 (48-70) 49.21 (7-60) 44.09a (15-59) K-W 1.97 
SF-36 Mental Component Score 51.20 (13-58) 46.11a (28-60) 41.34a (27-59) K-W 3.98 
      
*** <.000; ** < .01; * <.05      
A = ANOVA, K-W = Kruskal-Wallis      
aScores < 47  indicates  impaired HRQoL     
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applied so effects are reported at a .025 level of significance (.05/2). Effect sizes (r) for 
significant findings ranged from 0.4 to 0.7. Mann Whitney post hoc tests demonstrated a 
significant difference between PAPS thrombosis patients and controls on Physical 
Functioning (U = 50.5, r = -.05), Role Physical (U = 23.5, r = -0.7), Bodily Pain (U = 63.0, r 
= -0.4), General Health (U = 26.5, r = 0.7). Bonferroni’s test showed a significant difference 
(p < .01) between controls (M = 53.54, SD = 8.24) and PAPS thrombosis patients (M = 40.22, 
SD = 11.20) on the Vitality subscale. Significant differences between PAPS pregnancy 
patients and controls on these subscales were also found: Physical Functioning (U = 54.00, r 
= - 0.5), Role Physical (U = 25.50, r = 0.6), Bodily Pain (U = 41.00, r = 0.6), General Health 
(U = 20.50, r = 0.7). Bonferroni’s test showed a significant difference between controls (M = 
53.54, SD = 8.24) and PAPS pregnancy patients (M = 43.13, SD = 11.18) (df = (2), p ≤ .025) 
on the Vitality subscale.   
 
Neuropsychological assessment and HRQoL 
To investigate whether observed neuropsychological outcomes were associated with 
the eight SF-36 subscales and PCS and MCS scores, correlational analyses were carried out.  
To avoid bias and determine false discovery rate, all neuropsychological outcomes were 
entered into the analysis, not just those shown to be impaired on the group analysis (Tables 
5A and 5B, Appendix R). 
Pearson’s and Spearman’s correlations revealed that there were eight 
neuropsychological outcomes in all three cognitive domains that significantly correlated with 
HRQoL on all of the MCS subscales in the PAPS thrombosis patients group indicating an 
association between cognitive functioning and aspects of mental health. WASI Block Design, 
r = .48, p (one-tailed) < .05, Matrix Reasoning, r = .52,  p (one-tailed) < .05, WASI 
Performance IQ, r =.58, p (one-tailed) < .05 and BIRT Figure Recall Delayed, r = .45, p (one-
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tailed) < .05 were significantly related to Role Emotional; WAIS Digit Span was significantly 
correlated with Mental Health, r = .50, p (one -tailed) < .05; DKEFS Trail Making 2 was 
significantly related to Vitality, rs = .56, p (one-tailed) < .05, and CSRMT-F was significantly 
related to Social Functioning, rs =.55 r = .50, p (one-tailed) < .05. Three subtests were 
significantly correlated with the MCS; Digit Span, r = .59, p (one -tailed) < .05, DKEFS Trail 
Making 1, r = .51, p (one-tailed) < .05 and CSRMT-F, rs = .47, p (one-tailed) < .05. One 
neuropsychological outcome (DKEFS Trail Making 2) was significantly correlated with one 
PCS subscale, General Health, r = .58, p (one -tailed) < .05. CSRMT-F was also significantly 
related to the PCS, rs = .56, p (one -tailed) < .05. These findings indicate some association 
between executive functioning and memory and aspects of physical health. 
 In PAPS pregnancy patients, there were five neuropsychological outcomes in two 
cognitive domains (executive functioning and memory) that significantly correlated with three 
PCS subscales: WASI Digit Symbol Coding, r = .50, p (one -tailed) < .05, DKEFS Trail 
Making 4, rs =.49, p (one -tailed) < .05 and CSRMT-F, r =. 59, p (one -tailed) < .01 all 
significantly correlated with Role Physical, WAIS Digit Span, r = .52, p (one -tailed) < .05 
was significantly related to General Health.  There was a significant relationship between 
CSMT-W on the MCS rs = .45, p (one-tailed) < .05 and 2 MCS subscales; Role Emotional rs 
= .60, p (one -tailed) < .01 and Mental Health, rs = .48, p (one -tailed) < .05. The DKEFS 
Trail Making 4 was also significantly correlated with Mental Health, rs = .57, p (one-tailed) < 
.05  
 There were a further twenty neuropsychological outcomes in PAPS pregnancy patients 
which significantly correlated with HRQoL scores compared with six in the PAPS thrombosis 
group. These correlations were not in the expected direction and were not consistent with the 
hypothesis. Details can be seen in Tables 5A and 5B (Appendix R). Findings are only 
summarised in this text and will be addressed in the discussion. In PAPS pregnancy patients, 
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nine of the 20 significantly correlated neuropsychological variables in all 3 cognitive domains 
related to Physical Functioning, Role Physical, Bodily Pain, Vitality, Role Emotional and the 
PCS. Eleven outcomes within the domains of memory and executive functioning were 
significantly related to Role Physical, General Health, Mental Health and PCS. In PAPS 
thrombosis patients, neuropsychological outcomes within memory and executive functioning 
were significantly correlated with Bodily Pain, General Health, Vitality, Social Functioning 
and Role Emotional.  
 To evaluate the extent to which neuropsychological outcomes predict domains of 
HRQoL multiple regression analyses were calculated where two or more neuropsychological 
outcomes significantly positively correlated with SF-36 subscales scores and the MCS and 
PCS. SF-36 domains were entered as dependent variables. For Role Physical in PAPS 
pregnancy patients, the CSRMT-F and WAIS Digit Symbol Coding were all highly correlated 
when put into a regression model and became non-significant. This was also true for Role 
Emotional and WASI Performance IQ and BIRT Figure Recall Delayed and for the MCS and 
WASI performance IQ, DKEFS Trail Making 1 and CSRMT-F in PAPS thrombosis patients,. 
However these findings strengthen those of the correlation analysis. 
 
 
Discussion 
The aims of this study were to establish the characteristics and prevalence of 
neuropsychological deficits and impairments in HRQoL in patients with PAPS. A further aim 
was to identify relationships between cognitive functioning and HRQoL. As far as it is 
known, this is the first study to investigate these variables in this clinical population.  
 In comparing neuropsychological outcomes in terms of estimated pre-morbid IQ, as 
assessed by the NART, and obtained current IQ, as measured by the WASI, PAPS thrombosis 
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patients appeared to demonstrate a significant deterioration in their general intellectual 
abilities. Further comparisons on individual cognitive variables demonstrated significantly 
poorer functioning in the PAPS thrombosis group compared with controls on measures of 
visual memory (CSRMT-F) and executive functioning (WASI Symbol Search; DKEFS Trail 
Making 1 and 5). PAPS pregnancy patients also performed more poorly on these measures 
compared to controls though not significantly. These findings are consistent with previous 
research in patients with PAPS (Aharon-Peretz et al., 1995; Mikadashi & Kay, 1996) and SLE 
patients with aPL antibodies (Denburg et al., 1997). Together these results suggest a pattern 
of neuropsychological deficits associated with PAPS and aPL antibodies relating to memory 
and more convincingly, executive functioning.  
 The findings indicate that cognitive impairment occurred more frequently in PAPS 
thrombosis patients (n=8) compared to PAPS pregnancy patients (n=4). A noteworthy finding 
was that PAPS groups showed a higher proportion of impairment on a primary measure of 
executive functioning (DKEFS Trail Making 4) and verbal/auditory memory (BIRT Story 
Recall) compared to other outcomes.   
 Although an association between executive functioning and memory is recognised, 
differential patterns and associations between clinical populations is unclear (O’Brien et al., 
2009). The implications for impairment in executive function include difficulties in planning, 
initiation, sequencing and monitoring of complex goal directed behaviour (Stuss & 
Alexander, 2000). As such, individuals may struggle to be independent, constructively self-
serving and productive (Lezak, 2004). Impairments or mild deficits in this domain have been 
found to predict decline in disability and are associated with poor quality of life (Klein et al., 
2003); poor HRQoL and the relationship between HRQoL in both the domains of executive 
function and memory is further evidenced in this study. 
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An assessment of HRQoL using subscales and summary scores of the SF-36 revealed 
that PAPS patients were impaired on most domains of HRQoL. The extent of this impairment 
is consistent with studies in SLE patients (e.g. Fortin, et al., 1998; Gladman, Urowitz, Ong, 
Gough, & Mackinnon, 1996; Sweet et al., 2004; Wang et al., 2001), with scores for PAPS 
thrombosis patients ranging from 4- 49% lower than controls. This suggests that this clinical 
population may be having difficulties adjusting to the challenges PAPS presents to their life 
roles, social relationships and physical and psychological health (Brennan, 2001; Charmaz, 
1983; Livneh & Antonak, 1997).  PAPS thrombosis patients were impaired on both physical 
and mental subscales and summary scores. Where this group has a higher prevalence of 
cognitive impairment, the findings are consistent with those in studies with SLE and MS 
patients (Utset et al, 2006; Amato, 2001). PAPS pregnancy patients were impaired mainly on 
mental health subscales. This may relate to mental health problems which have been found to 
be associated with pregnancy losses (Beutel, Deckardt, & Weiner, 1995).  There were 
significant differences between PAPS patients and controls on all physical subscales and only 
one mental health subscale, Vitality. This was surprising given findings from research in 
similar clinical populations, which has found significant differences on all subscales and 
summary scores (Tam et al., 2008).  However, the scores on Role Emotional, Mental Health 
and the MCS of healthy controls were almost below cut off; this is important to consider 
when interpreting the findings.  
 This study offers an initial exploration of the relationship between neuropsychological 
functioning and HRQoL. It was hypothesised that these variables would be positively 
correlated. Although moderate in strength, some correlations were in the expected direction 
and are consistent with findings from previous research. There were fewer outcomes 
significantly correlated with HRQoL in PAPS pregnancy patients compared with the PAPS 
thrombosis patients. Executive functioning was associated with mental health in both groups, 
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which is consistent with findings in patients with SLE (Tam et al., 2008) as well as physical 
health, a finding supporting that of Cutajar et al. (2000). Memory (CSRMT-W) was 
associated with physical and mental health in PAPS pregnancy patients, including the 
physical and emotional impact that PAPS has on their ability to fulfil roles in life such as 
work and other activities. Role limitation due to mental health was also associated with 
memory (CSRMT-F) in PAPS thrombosis patients, supporting findings of Panopalis et al. 
(2007).  
 Although not strong, there were a number of significant negative correlations. Other 
potential confounding variables that may be associated with HRQoL were not addressed, such 
as disease activity, disease duration, illness related behaviours, coping style, social support 
(McElhone, Abbott, & Teh, 2006) and illness perceptions (Weinman, Petrie, Moss-Morris, & 
Horne, 1996). Subjective cognitive dysfunction may also be a variable associated with 
HRQoL (Vinck, Put, Arickx, & Medaer, 1997), particularly where patients overestimate their 
cognitive difficulties (Harrison & Ravdin, 2006). Although investigating these variables was 
beyond the scope of this study, they do warrant exploration.  
 Regarding the clinical significance of the findings, it is noted that the size of the 
effects in comparing PAPS patients with controls ranged from medium (.40) to large (1.9). 
These are comparable to effect sizes observed in studies of cognitive impairment in patients 
with SLE who test positive for aPL antibodies compared with controls (Denburg et al., 1997). 
Furthermore, the prevalence of impairment in PAPS patients is comparable to that identified 
in a number of studies in SLE with and without CNS involvement (Denburg & Denburg, 
2003; Monastero et al., 2001). This patient group is acknowledged to have clinically 
significant deficits; these results highlight the clinical importance of cognitive deficits found 
in PAPS, particularly those with PAPS thrombosis.  In addition, HRQoL in PAPS is poor and 
this too is comparable to other clinical populations, also highlighting the importance of a 
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broad range of psychological, social, physical and somatic factors associated with chronic 
illness that are impaired in PAPS, some of which are associated with deficits in executive 
function and memory.  
 Studies exploring psychological factors in patients with PAPS are few. As this clinical 
population is expected to grow (Kasthuri & Roubey, 2009), it is important to consider future 
research that can inform the development of treatment approaches. The limitations and 
challenges of this study highlight areas for methodological improvements in future studies as 
well as further variables to explore. 
While this study incorporated comprehensive inclusion/exclusion criteria, laboratory 
testing for aPL antibodies at the time of neuropsychological assessment may have 
strengthened the findings as would Magnetic Resonance Imaging (MRI) data to confirm the 
presence of other clinical features of CNS involvement in the clinical sample. Although the 
sample size may be regarded as limitation of the study, these initial findings are of interest 
and suggest a larger scale study is warranted. It is also important to acknowledge potential 
confounding variables, as referred to above, which may have explained the variance in 
HRQoL. It would be of interest to explore these variables further although not necessarily in 
association with cognitive functioning.  
This study highlights the challenges of conducting neuropsychological research where 
it can be burdensome for patients to complete such large batteries at one time while also 
including other variables. A further issue in conducting neuropsychological research 
involving large batteries concerns the resources available in terms of time and availability of 
professionals to administer assessments. This investigation included four assessors which has 
implications for reliability and as such is another limitation of this study. When considering 
this in future research, it would be prudent to address the importance of consistency in 
assessments and assessors such that studies are comparable and evidence is strengthened.  
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Conclusion 
In summary, significant associations between PAPS thrombosis patients and cognitive 
dysfunction were found; in particular general intellectual abilities have declined and there are 
deficits in executive functioning and visual memory. PAPS patients, particularly those with 
PAPS thrombosis, experience poor HRQoL; both physical and mental aspects of HRQoL 
were found to be associated with executive function and memory. These findings indicate the 
importance of monitoring cognitive functioning in this population in those with and without 
overt CNS involvement. It also emphasises the need for the provision of interventions such as 
cognitive rehabilitation and psychological therapies, both of which may facilitate improved 
adjustment and quality of life in patients with PAPS.    
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Introduction 
This critical review is structured to address four specific questions providing a reflective 
account of how involvement in this project has contributed to the researcher’s skills and 
abilities and highlighted areas where further learning is necessary. The review also discusses 
further clinical applications and research for cognitive functioning and health related quality 
of life (HRQoL) in patients with primary Antiphospholipid syndrome (PAPS).  
 
What research skills have you learned and what research abilities have you developed from 
undertaking this project and what do you think you need to learn further? 
The salient learning experiences for me, included skills acquired in the processes of 
problem solving and formulation, reviewing existing work and conceptual thinking and 
working collaboratively with motivated and dedicated health professionals. 
There has been little research in primary APS but there is some evidence suggesting 
cognitive impairment in PAPS based on similar clinical populations. The process of gaining 
knowledge about PAPS and then reviewing this evidence was complex as much of what had 
been written was by physicians for medical journals and books. Working through this to 
create a logical and coherent argument for the study and the methodology challenged and 
developed my critical and conceptual thinking skills far more than any other assignment I 
have done during training. I believe the medical details and complexities of APS contributed 
to this but it was a very fulfilling part of the work for me given my interest in health 
conditions.  
Although communicating the reasons for the research has been a skill I have used 
throughout the project, there are some key events that were important for me in relation to 
this. At the beginning I had to apply for further funding for research resources by explaining 
the research and requesting support. These skills were further employed at the ethics review 
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where I discussed the details of the methodology more specifically and clarified concerns of 
the committee. The process gave me confidence that the research was valid and in discussing 
it I realised that I had the knowledge and ability required to take the project further.   
Although challenging, the most enjoyable part of the project has been working 
collaboratively with other health professionals. Teamwork has been integral the success of the 
project. Initially, my role was to create a team, communicate the value of the research and 
involve professionals who could fulfil the role of providing expertise in PAPS and assist in 
recruitment of participants. This was achieved within a specific medical context where there 
was no direct input from psychology. Working alongside those medical professionals 
provided me with an opportunity to demonstrate the role psychology can have in a physical 
health service.  
Once the project started, the most important aspect was communicating with team 
members regularly, taking the time to maintain good relationships with each of them and 
keeping them motivated to meet recruitment targets. This is vital in research, especially when 
individuals are busy with the many other aspects of their day to day work roles in busy 
services where recruitment is not always at the forefront of their minds. As well as regularly 
visiting the team, I attended team research meetings to present the project to all health 
professionals related to the service with the aim of increasing awareness of the project and the 
need for participants.  
Juggling this project with the demands of placement and other assignments meant that 
my organisational skills were put to the test and being as organised as possible was the only 
way to ensure the project would run smoothly. I was surprised at the length of time it took to 
organise appointments with participants. Although this could be time consuming when 
participants had many questions or experiences they wished to share it was also hugely 
interesting and rewarding and I regarded it as a very important part of the process. 
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Coordinating meeting with participants with the availability of research assistants and having 
access to one set of testing equipment was challenging at times. I was, however, well 
supported by the research assistants who were vital to this project.  
Managing the data and conducting the analysis is a key research skill. Understanding 
the appropriate statistical analyses for this study has been satisfying and has given me the 
confidence to attempt quantitative research with statistical analyses in future. 
Disseminating the findings of the study has been a valuable exercise in developing the 
ability to communicate scientific findings and tailoring the communication of the findings to a 
variety of audiences including the participants, the trustees of the Hughes Syndrome 
Foundation and the ethics committee. In writing up this project I have gained skills in 
communicating the study in a style specific to what is expected in the presentation of 
scientific research. It has highlighted to me the significance and challenges of conducting 
research ethically and being responsible and accountable for your work as a researcher. 
In terms of further learning I think the main areas lie in different methodologies and 
larger projects. This project was on a small scale and so the skills learned are within that 
context. Larger scale projects across a number of sites with many more participants and many 
more health professionals working as part of a team would be more demanding on many 
levels. However, the skills learned on this project are transferable and would inform my 
working on a larger project. In terms of other methodologies, this study was a cross-sectional 
study and as such I now have the skills to apply this methodology again. I hope that in the 
future I have the opportunity to learn other quantitative as well as qualitative methodologies. 
 
If you were able to do this project again what would you do differently and why? 
There are practical aspects of this study which may have helped the project run more 
efficiently which I would have done differently. Mainly having the use of only one set of tests 
meant that only one participant could be assessed at any one time. This restricted the 
  81 
recruitment process which was not ideal given the timescale of the project. Another aspect 
related to this is the time I had available to be on site when medical staff were recruiting for 
the study. While I was not able to identify potential participants as I did not have access to 
their medical records, there are times when I believe it would have been helpful for me to be 
present more often during clinic hours when recruitment took place. Having a member of the 
research team with a dedicated role of discussing the project and answering queries of 
potential participants might have taken some pressure off the medical team members who had 
their professional roles to carry out as well as helping with the recruitment.  An important 
learning point relating to the difficulties with recruitment is that when the project was being 
planned, the certainty about the pool of possible participants was considered to be ample for 
the sample size needed. Once the inclusion/exclusion criteria were applied, however, this pool 
decreased. In future, I will give this more consideration so that I can plan accordingly.  
An aspect of the project that I struggled with relates to my concerns around ethical 
practice. The participants in this study were not offered feedback on their assessments. This 
was made clear to them before they consented to take part and this is line with ethical practice 
(British Psychological Society (BPS, 2004a; BPS, 2004b), nonetheless, some participants 
expressed their regret about this. Unfortunately, I did not have the resources to provide any 
reports but when ‘debriefing’ (BPS, 2004a) with participants about the experience of being 
assessed, I offered brief feedback about their performance. I also communicated to them that I 
was available to discuss it at any time should they wish to contact me with questions or 
concerns.  
Another important change I would have made concerns MRI brain scans and 
laboratory testing. Had there been the time and resources I believe it would have been helpful 
to include MRI brain scan data to confirm central nervous system involvement in participants 
and to take blood tests for all participants at the time of the assessments. This would have 
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allowed a comparison to be made between the level of antiphospholipid antibodies in 
participants’ blood and performance on the neuropsychological assessments. In doing so, this 
may have provided further information about the relationship between the antibodies and 
cognitive impairment in this clinical population. 
 
 As a consequence of doing this study, would you do anything differently in regard to making 
clinical recommendations or changing clinical practice, and why? 
APS is a relatively recently discovered disease and as such there is scarce research relating to 
psychological correlates of the condition. However as a chronic illness there is much that can 
be learned from studies relating to other autoimmune and chronic diseases such as Systemic 
lupus erythematosus (SLE), Multiple Sclerosis and Cancer where there is evidence suggesting 
the value of psychological interventions (Brennan, 2001; Mitchell, Kemp, Benito-Leon & 
Reuber, 2010, Navarrete-Navarrete et al., 2010) . In view of this, I believe that there are some 
important clinical recommendations to make and changes to clinical practice that could be 
made to serve those with PAPS.   
Given the challenges associated with coping with this disease, patients and their 
families may benefit from interventions that facilitate adaptive coping/functioning and 
address psychological distress associated with having or caring for someone with the disease. 
This may include i) supporting patients to be informed and knowledgeable about their 
condition ii) providing psychoeducation to promote healthy behaviours (e.g. medication and 
stress management) iii) encouraging patients to focus on and develop goals relating to their 
talents and abilities and iv) promoting attendance at patient forums and setting up support 
groups (Iverson, 1995).  
 In terms of neuropsychology, deficits in cognitive skills could be tracked over 
the course of the illness and considered in relation to pharmacological interventions. 
  83 
Psychological interventions addressing strengths and weaknesses could be designed to 
promote optimal social, occupational and educational adjustment. Patients and their families 
may feel reassured to know that their experiences of poor memory and/or flexibility in 
thinking may be associated with PAPS as opposed to any other conditions or mental health 
problem.   
In practice, I would  recommend i) building relations within the service, ii) informing 
and educating physicians about the role psychology can provide by presenting the evidence 
base for psychological interventions with other clinical populations and iii) clarifying the 
referral pathway by which those with PAPS can access psychology.   
 
If you were to undertake further research in this area what would that research project seek 
to answer and how would you go about doing it? 
There is much scope for further investigation of cognitive functioning and HRQoL in 
this clinical population.  I would be interested in carrying out a larger scale study with more 
cognitive assessments and more participants but if one considers the evidence from other 
studies with similar clinical populations there are many variables that may be associated with 
these two aspects of PAPS.  
As HRQoL can be considered to be a measure of adjustment to chronic illness, I 
would seek to explore the length of time since the disease had been diagnosed and compare 
this with illness perceptions, coping strategies and HRQoL. In this I would seek to answer 
whether there is an association between the period an individual has lived with a diagnosis of 
disease, the extent to which they have adjusted to having the disease, the coping strategies 
they employ in their illness experience and how they perceive their illness affects their lives. 
This could also include measures of executive functioning to determine whether any deficits 
are associated with those variables.  
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Where some patients with PAPS may be referred for psychological input, it would be 
interesting to compare HRQoL in those who have and have not had psychological 
intervention. If there were enough participants who had received a particular model of therapy 
it would be useful to measure the effectiveness of that particular model versus another with 
this clinical population. 
  I would also undertake research with this population using qualitative methodologies. 
Where many patients with PAPS struggled to have their illness validated and the disease 
diagnosed, it would be useful to explore the experiences of individuals and the impact this 
struggle has had on their lives. These experiences would most likely relate to aspects 
considered within the concept of quality of life but would provide a different, perhaps more 
detailed understanding. Where such studies have not been done, this is a clinical population 
who may want their experiences to be recognised in this way. In my meeting with participants 
for this study, this is the impression I gained and I believe there would be real value in 
exploring this qualitatively. Furthermore it could potentially provide a basis from which to 
inform further studies employing quantitative methods e.g. using more specific and 
meaningful psychological measures. 
Many of the procedures I went through for this project would be required for each of 
the research ideas described above. The practicalities would be similar but I believe one of the 
key aspects would be to ensure there is a research team motivated to pursue the study. My 
experience of those members from the service from which this project was based is that it is a 
service and research unit that is dedicated to research in the field and that they would fully 
support further investigations.  
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Appendix A  
 
Electronic Search for Literature Review 
 
The literature was reviewed in 2010 and 2011 using electronic databases, including 
PsycINFO, PUBMED, MEDLINE, CINAHL, Sciencedirect, EBSOhost and 
EMBASE to search for research articles published between 1980 and 2011. The 
following search terms were applied for literature pertaining to antiphospholipid 
syndrome, cognitive functioning and quality of life: antiphospholipid syndrome / 
antiphospholipid antibodies/ lupus/ SLE/ hughes syndrome AND cognitive 
dysfunction/ memory/ quality of life. Search terms applied for literature specific to 
chronic illness and health related quality of life included: chronic illness AND 
coping/adjustment/adaptation/health related quality of life. Search terms relating 
neurological conditions and health related quality of life included: neurological 
conditions/stroke/multiple sclerosis/tumours/ AND quality of life.  
These search terms were applied to all published literature including peer-
reviewed papers and chapters in books, published in English. 
Abstracts of references were read and articles sought where the abstract 
indicated that the paper described an empirical investigation or theoretical discussion 
relevant to the area of antiphospholipid syndrome, cognitive functioning and quality 
of life. A manual search of reference lists was also conducted to identify further 
relevant literature. 
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 (TRUST LOGO HERE) 
 
 
PATIENT INFORMATION SHEET 
 
Study title: 
 
Difficulties with memory and thinking processes, and quality of life in 
Antiphospholipid Syndrome (APS) 
 
You are being invited to take part in a research study for people with APS. 
Before taking part it is important that you understand why the research is 
being done and what taking part involves. Please read the following 
information carefully. Feel free to discuss it with relatives, friends or your GP if 
you wish. You can also contact the researcher directly if there is anything that 
you would like to discuss further. Please see page 3 for contact details.  
 
What is the purpose of the study? 
It has been found that many patients with APS complain of difficulties with 
remembering and learning new information in addition to slowness in their 
thinking. Research has also shown that patients with similar chronic illnesses 
experience difficulty in coping with their condition, finding it physically and 
emotionally challenging. We know these problems occur but information is 
lacking about the precise difficulties experienced.   
 
By studying groups of sufferers of this disease we hope to find out several 
things. Firstly, we hope to determine what proportions of people with this 
condition are affected with memory and cognitive (‘thinking’) problems. 
Secondly we hope to learn whether there are any recurrent patterns of 
memory and cognitive difficulty, which are characteristic of APS. Thirdly we 
want to know the how those with APS might be affected physically and 
emotionally by their condition.  
 
Why have I been chosen? 
We need to recruit 45 participants in total. If you have been asked to take part 
it will be because you have been diagnosed with APS.  
 
Do I have to take part? 
No, it is up to you whether you take part of not. If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still 
free to withdraw from the study at any time after having agreed to take part, 
without giving any reason. This will not affect your care or your entitlement to 
any support offered within your service.  
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What will happen to me if I decide to take part? What will I be asked to 
do? 
Providing you are suitable for the study and agree to take part, your doctor will 
allocate you to a group with others with the same characteristics of APS as 
you (i.e. pregnancy complications group, or the thrombosis characteristics 
group). A researcher will contact you and ask you to return to the clinic at a 
convenient time to you.  The researcher will not be told which group you are in 
i.e. the researcher will not be told whether you suffer from APS with 
thrombotic characteristics or pregnancy complications. It is important that you 
do not tell the researcher which group you are in as this could influence the 
results of the study.  
 
When you attend the appointment at the clinic, it will be to spend some time 
(approximately 2.5 hours) with a researcher who will do a range of simple 
tests designed to look for memory problems and difficulties with thinking. The 
tests involve paper and pencil and simply looking at words and pictures and 
recalling information. 
 
You will also be asked to complete a questionnaire booklet containing 
questions about your physical and emotional well-being, your thoughts and 
feelings about APS and about the way you generally cope with stressful 
situations. This booklet will take a maximum of 20 minutes to complete. 
 
All participants will be similarly assessed. Your assessment will be one-to-one 
over one visit lasting approximately 2.5 hours in total for all the tests to be 
completed. 
 
If you take part in this study, you will not have to change your medication and 
your usual treatment will not be affected in any way. 
 
If you experience distress during the time you are with the researcher, 
professional help is available at XXXXX. The researcher will ensure you 
receive this help. 
 
 
A letter will be sent to your GP by a member of the healthcare team to inform 
them that you are participating in this research. 
 
 What are the possible disadvantages and risks of taking part? 
The main disadvantage to taking part is the time involved in travelling to and 
attending appointment to completing the assessments. A risk of taking part is 
the possibility that in completing the assessments you experience some 
difficult emotions around the impact APS might be having on your well-being.  
 
What are the possible benefits of taking part? 
There will be no immediate benefit from taking part. The information we get 
from the study will contribute to our knowledge around memory and cognitive 
processes for APS patients and the impact APS has on your physical and 
emotional well-being. This information may help us to offer better support to 
APS patients. 
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What if new information becomes available? 
Sometimes during the course of study, new information becomes available 
which impacts the condition that is being studied. If this happens the 
researchers will tell you about it and discuss with you whether you want to or 
should continue in the study. If you decide to withdraw, this will not influence 
the care you receive within the APS service. If you decide to continue you will 
asked to sign an updated consent form.    
 
 
What happens when the study stops? 
Once the study stops, there will be nothing further for you to do. Your care at 
XXXXX will not be impacted upon at any time during or after the study.  
 
Will my taking part in this study be kept confidential? 
Yes. All the questionnaires and information given by you will be confidential 
and coded to make it anonymous. This means that your name will not appear 
on any of your questionnaires. Questionnaires will be numbered and numbers 
will be linked to your name on a password-protected file. All information 
collected about you during the study that leaves the clinic will be kept strictly 
confidential in accordance with the Data Protection Act 1998. Data from this 
study will be retained for 10 years and subsequently disposed of securely.  
 
What happens to the results of the study? 
The study will be written up for publication in scientific journals and/or may be 
presented at scientific conferences. You will not be identified in any 
publication of presentation. If you would like to know the results of the study, 
we can provide you with a summary sheet.   
 
Who is organising the research? 
The study is being conducted by Lucy Tinning, a Trainee Clinical Psychologist 
from Salomons: Canterbury Christ Church University clinical psychology 
training programme. The research is supervised by XXXXX from Salomons 
and XXX from XXXX NHS Trust. 
 
Who else can I speak to about this research to get independent advice? 
You can speak with a member of the Hughes Syndrome Foundation 
organisation. Their contact details are: 
 
 
Telephone:  
Email:  
Contact:  
 
 
 
 
 
 
 
  95 
 
 
 
 
 
Contact for further information 
If you would like to discuss your potential involvement further please contact: 
 
Name:Lucy Tinning  
Job title: Trainee Clinical Psychologist  
Telephone number:  
Email address:  
Address:  
 Department of Applied Psychology 
 Canterbury Christ Church University 
 Salomons Campus  
 Broomhill Road  
 Tunbridge Wells 
 Kent  
 TN3 0TG  
 
If I decide to take part and want to make a complaint at any time, who 
can I contact? 
You can talk to the hospital's Patient Advice and Liaison Service (PALS), 
which provides support to patients, their families and visitors.  Please ask a 
member of staff to direct you to their office or you can call xxx for the PALS 
team at XXXXX . 
 
If you are not satisfied with the response that you receive, you can make a 
formal complaint in the following ways:  
 
 
• Telephone the complaints department on  
• Email your complaint to   
• Write to the Chief Executive, at the address below  
• Write to the complaints department at the address below 
 
Address: 
XXXXXX 
 
In the event that something does go wrong and you are harmed during the research and 
this is due to someone‘s negligence then you may have grounds for a legal action for 
compensation against Canterbury Christ Church University and or XXXXX NHS Trust but 
you may have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate). 
 
 
 
If I decide to take part and I experience distress and wish to seek 
support, who can I contact? 
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You can seek support from The Hughes Syndrome Foundation (contact 
details provided on page 3) or you can seek help from your GP. 
 
If you experience distress during the time you are with the researcher, 
professional help is available at XXXX. The researcher will ensure you receive 
this help. 
 
Who has reviewed this study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by XXXX Research Ethics Committee. 
 
 
 
Thank you for taking the time to read this information sheet 
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(TRUST LOGO HERE) 
 
PARTICIPANT INFORMATION SHEET 
 
Study title: 
 
Difficulties with memory and thinking processes, and quality of life in 
Antiphospholipid Syndrome (APS) 
 
You are being invited to take part in a research study for people with APS. 
Before taking part it is important that you understand why the research is 
being done and what taking part involves. Please read the following 
information carefully. Feel free to discuss it with relatives, friends or your GP if 
you wish. You can also contact the researcher directly if there is anything that 
you would like to discuss further. Please see page 3 for contact details.  
 
What is the purpose of the study? 
It has been found that many patients with APS complain of difficulties with 
remembering and learning new information in addition to slowness in their 
thinking. Research has also shown that patients with similar chronic illnesses 
experience difficulty in coping with their condition, finding it physically and 
emotionally challenging. We know these problems occur but information is 
lacking about the precise difficulties experienced.   
 
By studying and comparing groups of sufferers of this disease and those 
without the disease we hope to find out several things. Firstly, we hope to 
determine what proportions of people with this condition are affected with 
memory and cognitive (‘thinking’) problems. Secondly we hope to learn 
whether there are any recurrent patterns of memory and cognitive difficulty, 
which are characteristic of APS. Thirdly we want to know the how those with 
APS might be affected physically and emotionally by their condition.  
 
Why have I been chosen? 
We need to recruit 45 participants in total. Twenty participants include those 
who do not have APS. If you have been asked to read this information sheet, 
it will be because you do not have APS.  
 
Do I have to take part? 
No, it is up to you whether you take part of not. If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still 
free to withdraw from the study at any time after having agreed to take part, 
without giving any reason.  
 
What will happen to me if I decide to take part? What will I be asked to do? 
Providing you are suitable for the study and agree to take part, the researcher 
will contact you and ask you to return to the clinic at XXXX at a convenient 
time to you. When you attend the appointment at the clinic, it will be to spend 
some time (approximately 2.5 hours) with a researcher who will do a range of 
simple tests designed to look for memory problems and difficulties with 
Appendix G 
 
Participant Information Sheet 
for Healthy Control Participants 
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thinking. The tests involve paper and pencil and simply looking at words and 
pictures and recalling information. 
 
You will also be asked to complete a questionnaire booklet containing 
questions about your physical and emotional well-being. This booklet will take 
a maximum of 20 minutes to complete. 
 
All members of the groups will be similarly assessed. Your assessment will be 
one-to-one over one visit lasting approximately 2.5 hours in total for all the 
tests to be completed. 
 
If you experience distress during the time you are with the researcher, 
professional help is available at XXXXX Hospital. The researcher will ensure 
you receive this help. 
 
 What are the possible disadvantages and risks of taking part? 
The main disadvantage to taking part is the time involved in travelling to and 
attending appointment to completing the assessments. 
 
What are the possible benefits of taking part? 
There will be no immediate benefit from taking part. The information we get 
from the study will contribute to our knowledge around memory and cognitive 
processes for APS patients and the impact APS has on their physical and 
emotional well-being. This information may help us to offer better support to 
APS patients. 
 
What if new information becomes available? 
Sometimes during the course of study, new information becomes available 
which impacts the condition that is being studied. If this happens the 
researchers will tell you about it and discuss with you whether you want to 
continue in the study. If you decide to continue you will asked to sign an 
updated consent form.    
 
What happens when the study stops? 
Once the study stops, there will be nothing further for you to do.  
 
Will my taking part in this study be kept confidential? 
Yes. All the questionnaires and information given by you will be confidential 
and coded to make it anonymous. This means that your name will not appear 
on any of your questionnaires. Questionnaires will be numbered and numbers 
will be linked to your name on a password-protected file. All information 
collected about you during the study that leaves the clinic will be kept strictly 
confidential in accordance with the Data Protection Act 1998. Data from this 
study will be retained for 10 years and subsequently disposed of securely.  
 
What happens to the results of the study? 
The study will be written up for publication in scientific journals and/or may be 
presented at scientific conferences. You will not be identified in any 
publication of presentation. If you would like to know the results of the study, 
we can provide you with a summary sheet.   
  99 
 
Who is organising the research? 
The study is being conducted by Lucy Tinning, a Trainee Clinical Psychologist 
from Salomons: Canterbury Christ Church University clinical psychology 
training programme. The research is supervised by XXXX from Salomons and 
XXXXX from XXXXX. 
 
Who else can I speak to about this research to get independent advice? 
You can speak with a member of the Hughes Syndrome Foundation 
organisation. Their contact details are: 
 
 
Telephone:  
Email:  
Contact:  
 
 
Contact for further information 
If you would like to discuss your potential involvement further please contact: 
 
Name:Lucy Tinning  
Job title: Trainee Clinical Psychologist  
Telephone number 
Email address:  
Address:  
 Department of Applied Psychology 
 Canterbury Christ Church University 
 Salomons Campus  
 Broomhill Road  
 Tunbridge Wells 
 Kent  
 TN3 0TG  
 
 
If I decide to take part and want to make a complaint at any time, who 
can I contact? 
You can talk to the hospital's Patient Advice and Liaison Service (PALS), 
which provides support to patients, their families and visitors.  Please ask a 
member of staff to direct you to their office or you can call  XXX for the PALS 
team at XXXXX. 
 
If you are not satisfied with the response that you receive, you can make a 
formal complaint in the following ways:  
 
 
• Telephone the complaints department on  
• Email your complaint to  
• Write to the Chief Executive, at the address below  
• Write to the complaints department at the address below  
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Address: 
 
In the event that something does go wrong and you are harmed during the research and 
this is due to someone‘s negligence then you may have grounds for a legal action for 
compensation against Canterbury Christ Church University and or  XXXX NHS Trust but 
you may have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate). 
 
 
If I decide to take part and I experience distress and wish to seek 
support, who can I contact? 
You can seek support from The Hughes Syndrome Foundation (contact 
details provided on page 3) or you can seek help from your GP. 
 
If you experience distress during the time you are with the researcher, 
professional help is available at XXXX. The researcher will ensure you receive 
this help. 
 
Who has reviewed this study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by XXXX Research Ethics Committee. 
 
 
 
Thank you for taking the time to read this information sheet 
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Appendix H 
 
Consent form for Patients and Healthy Control Participants 
 
(TRUST LOGO) 
 
         PATIENT CONSENT FORM 
 
CONSENT FORM FOR RESEARCH STUDY 
Title of Project: Difficulties with memory and thinking processes, and quality of 
life in Antiphospholipid Syndrome (APS) 
Name of Researcher: Lucy Tinning 
  Please tick 
to confirm 
I confirm that I have read and understand the information 
sheet for the above study.  
   
-----
  
I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected.  
   
-----
  
I have been given full information regarding the aims of the 
research and have been given information with the 
researcher’s name on and a contact number and address if I 
require further information. 
   
-----
  
I understand that all personal information provided by 
myself to the researchers and clinician will remain 
confidential and no information that identifies me will be 
made publically available 
   
-----
  
I agree to take part in the above research study.  
   
-----
  
 
 
Name of Participant 
 
Date 
 
 
Signature 
__________________________ 
 
Researcher 
____________  
 
Date 
_________________________ 
 
Signature 
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Appendix I 
 
Template Letter to Patients’ GP re. Participating in the Research 
 
 
 
(NHS TRUST LOGO) 
Hospital address 
 
(Date) 
 
 
 
 
RE Name/DOB 
 
 
 
Dear Dr 
 
This letter is to notify you that (patient) has decided to participate in the 
research study below:  
 
Difficulties with memory and thinking processes, and quality of life in 
Antiphospholipid Syndrome (APS) 
 
This research is based at Xxxxxx, London. 
 
If you have any concerns about this, please do not hesitate to contact me. 
 
 
Yours sincerely 
 
 
Dr (Name of Consultant or Research Nurse) 
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Appendix J 
 
Cover Letter to Participants re. Summary of Research Findings 
 
 
 
 
 
 
 
 
 
 
Clinical Psychology Programme 
Broomhill Road 
Tunbridge Wells 
Kent 
TN3 0TG 
 
[Participant name] 
[Participant address] 
 
13th July 2011 
 
 
Dear Ms [Participant surname] 
 
 
Re. Your participation in my research project entitled:  
 
“Difficulties with memory and thinking processes, and quality of life in 
Antiphospholipid Syndrome” 
 
I would like to thank you again for participating in this research project – your 
participation was enormously valuable and Karen, Hannah, Sabrina and I enjoyed 
meeting with you. 
 
 You indicated that you would like to be sent a summary of the research 
findings. I am writing to let you know that I have recently completed the research 
and I have therefore enclosed the summary with this letter.  
 
 
Thank you again and I wish you all best for the future. 
 
Yours sincerely  
 
 
Lucy Tinning 
Trainee Clinical Psychologist 
 
Centre for Applied Social & Psychological Development 
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Appendix K 
 
Summary of Research Findings for Participants 
 
Research Summary: 
Difficulties with memory and thinking processes, and quality of life in 
Antiphospholipid Syndrome 
 
Researcher: Lucy Tinning, Trainee Clinical Psychologist,  
       Canterbury Christ Church University 
Supervisors: Dr. Paul Camic, Professor Michael Kopelman 
 
 
Aims of the study: 
I was interested in investigating 1) whether there was a relationship between APS and 
memory and thinking problems and if so 2) what proportion of APS suffers had this 
experience and 3) whether there was a pattern to these difficulties.  I was also 
interested know the how those with APS might be 4) affected physically and 
emotionally by their condition and 5) whether thinking and memory problems were 
associated with this.  
 
Participants: 
All together, 45 people took part in the research, 30 had APS. Fifteen were allocated 
to an ‘APS - pregnancy complications’ group and fifteen were allocated to an ‘APS- 
thrombosis characteristics’ group. There were fifteen participants who did not have 
APS or any other underlying health problems. Everyone was asked the same questions 
and completed the same questionnaires as you. 
 
Analysis of responses: 
You ticked boxes with numbers next to them to indicate your responses to questions 
about physical and emotional well being. The questions in this questionnaire provided 
scores across 8 domains of physical and emotional well being. You also did a range of 
tests designed to look for memory problems and difficulties with thinking. I added up 
scores on every test completed to gain a total score for each test for every person. 
Scores from those with APS were compared with those participants who did not have 
APS (the ‘control’ group), to identify if there were any differences between those with 
and without APS. 
 
  105 
The statistical tests I used to explore the relationship between memory and 
thinking processes and physical and emotional wellbeing were based on everyone’s 
total scores considered together. For this reason, all of the findings of the research 
related to everyone’s responses as a whole, not just yours individually.  This means 
that personal experience of memory and thinking and physical and emotional well-
being may be different from the results described. If they are, please be assured that 
your responses to the questionnaires and tests were included in the analysis but on 
average; responses were consistent with the findings below. 
 
Findings: 
Results showed that people with ‘APS - thrombosis characteristics’ were twice as 
likely to experience memory and thinking problems compared to those with ‘APS - 
pregnancy complications’.  Furthermore, in comparison to those who do not have 
APS (‘control’ group participants), people with ‘APS- thrombosis characteristics’ did 
not perform as well on the tests of memory and processes that require flexible 
thinking, such as initiating and stopping actions, switching between different tasks 
and situations as well as skills related to moving muscle groups e.g. hand/finger 
muscles used for drawing.  People with ‘APS -thrombosis characteristics’ also 
demonstrated decreased levels in their general intellectual abilities when compared to 
their abilities before they had APS.  
Both APS groups demonstrated poor physical and emotional well-being. 
However, physical well-being was poorer. Participants considered their physical 
health to limit their physical functioning and perceived their general health status to 
be worse than those who did not have APS. APS participants experienced greater pain 
and perceived their activities or work to be limited by their physical health condition 
when compared with people who do not have APS.  Both groups of people with APS 
also felt more tired and less energetic compared to people without APS – this is 
influenced by emotional and physical problems. 
General intellectual abilities, memory and thinking processes were all 
associated with emotional wellbeing for ‘APS - thrombosis characteristics’ 
participants and thinking processes and memory were associated with physical well 
being in ‘APS - pregnancy complications’ participants. 
I hope that you find this summary helpful, and I would like to highlight again 
how valuable your contribution to this study has been. 
Lucy Tinning 
Trainee Clinical Psychologist 
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Appendix L 
Research Ethics Committee Declaration for End of Study 
 
This has been removed from the electronic copy 
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Appendix M 
 
Cover Letter to NHS Ethics Committee re. Summary of Research Findings  
 
 
 
 
 
 
 
 
 
Clinical Psychology Programme 
Broomhill Road 
Tunbridge Wells 
Kent 
TN3 0TG 
Mr David Ingram 
Committee Chair 
East London REC 2 
2nd Floor, Burdett House 
Mile End Hospital 
Bancroft Road 
London 
E1 4DG 
 
 
13th July 2011 
 
Study Title:   Cognitive functioning and quality of life in patients with      
Antiphospholipid Syndrome 
 
REC Reference:    10/H0704/39 
 
 
Dear Mr Ingram 
 
Thank you for granting the above research ethical approval on 13th July 2010. I 
am writing to inform you that the data collection for the above research study has 
now concluded. Please find enclosed a summary of the research and its findings. 
 
Please do not hesitate to contact me if you require any further information. 
 
Yours sincerely 
 
 
Lucy Tinning 
Trainee Clinical Psychologist 
Email: ljt29@canterbury.ac.uk 
Centre for Applied Social & Psychological Development 
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Appendix N 
Cover Letter to NHS R&D Department re. Summary of Research Findings  
 
 
 
 
 
 
 
 
Clinical Psychology Programme 
Broomhill Road 
Tunbridge Wells 
Kent 
TN3 0TG 
 
[Contact in Department] 
[NHS Trust] Research & Development Department 
[R&D Department Address] 
 
 
13th July 2011 
 
Study Title:   Cognitive functioning and quality of life in patients with      
Antiphospholipid Syndrome 
 
REC Reference:    10/H0704/39 
 
 
Dear [Contact] 
 
Thank you for granting the above research approval on 9th September 2010. I am 
writing to inform you that data collection for the study has now been concluded. 
Please find attached a summary of the research and its findings. 
 
Please do not hesitate to contact me if you require any further information. 
 
 
Yours sincerely 
 
 
Lucy Tinning 
Trainee Clinical Psychologist 
Email: ljt29@canterbury.ac.uk 
 
 
 
Centre for Applied Social & Psychological Development 
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Appendix O 
Summary of Research Findings for Ethics Committee and R&D Departments 
Research Summary: 
Cognitive Functioning and Quality of Life in Patients 
 with Antiphospholipid Syndrome 
REC Reference: 10/H0704/39 
 
Researcher: Lucy Tinning, Trainee Clinical Psychologist,  
       Canterbury Christ Church University 
Supervisors: Dr. Paul Camic, Professor Michael Kopelman 
 
Background and Aims:  
Antiphospholipid syndrome (APS) is an autoimmune disease and chronic 
illness characterised by thrombosis and recurrent pregnancy morbidity in association 
with laboratory blood tests confirming moderate-to-high titer antiphospholipid (aPL) 
antibodies and/or the presence of the lupus anticoagulant. It may occur as an isolated 
diagnosis, primary APS (PAPS), or it may be secondary, associated with other 
autoimmune disorders such as Systemic lupus erythematosus (SLE-related APS). A 
clinical feature of APS is cognitive dysfunction which may be a direct manifestation 
of central nervous system (CNS) involvement.  
Previous research has suggested that patients with aPL antibodies, secondary 
APS and PAPS experience cognitive deficits which can vary from mild 
neurocognitive disorders to severe global dysfunction in the context of dementia. 
However, research in this area is limited and studies have mainly included SLE 
patients testing positive for aPL antibodies. Research distinguishing secondary APS 
and PAPS patients specifically is more limited and mainly anecdotal. Findings so far 
have not identified any consistent pattern of cognitive dysfunction although there are 
similarities in the deficits found. Deficits have been identified in patients with and 
without CNS involvement in the disease. 
As an autoimmune disease, APS is a chronic illness and patients live with the 
condition without a prospect of cure.  The range of clinical features of APS, including 
cognitive dysfunction, are likely to impact upon aspects of patients’ health related 
quality of life (HRQoL), where they may be presented with changes in their life roles 
and social and familial relationships while they concurrently manage psychological 
distress, physical pain, ongoing medical treatment and restrictions in the activities of 
daily living.  
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Research exploring cognitive dysfunction in PAPS or the experience of illness 
using HRQoL measures could not be found at the time of this study. Findings of 
research exploring HRQoL in similar clinical populations, such as SLE, indicate that 
scores on HRQoL measures have been 30-40% lower than those reported by matched 
peers with all domains of HRQoL affected.  
This study aimed to explore the relationship between cognitive functioning 
and HRQoL in patients with Primary Antiphospholipid Syndrome (PAPS). Further 
aims of this study were to establish the characteristics and prevalence of cognitive 
dysfunction and HRQoL in PAPS 
 
Study Design: 
A cross-sectional study was employed, utilising a quantitative design 
 
Participants: 
Thirty adult females with a diagnosis of Primary Antiphospholipid Syndrome 
were recruited from (Name of Service and Hospital), (NHS Trust Name). Fifteen 
participants had experienced pregnancy complications (No CNS involvement in the 
disease) and fifteen participants had experienced a thrombotic event (CNS 
involvement in the disease). Fifteen healthy females were also included as a control 
group.  
 
Procedure: 
  Participants completed a range of self-report questionnaires and 
neuropsychological assessments designed to measure HRQoL and cognitive 
functioning across domains of general intelligence, executive functioning and 
memory. Statistical analyses were then conducted using the subscale and total scores 
on each measure for each participant. 
 
Results: 
Patients in the PAPS thrombosis group were twice as likely to be designated as 
cognitively impaired compared to patients in the PAPS pregnancy group. The findings 
also suggest that PAPS thrombosis patients had experienced a decrease in their 
general intellectual functioning compared to pre-morbid levels. This group also 
demonstrated lower performance on measures of memory and executive functioning 
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compared to healthy controls. PAPS pregnancy patients also performed more poorly 
on these measures compared to healthy controls although not significantly. Both 
groups demonstrated poor HRQoL across physical and mental subscales. Both groups 
were significantly more impaired in all physical domains and one mental domain of 
HRQoL compared to controls. Neuropsychological outcomes in general intellectual 
abilities, memory and executive functioning were significantly associated with mental 
HRQoL subscales in PAPS thrombosis and executive functioning and memory were 
significantly associated with physical HRQoL subscales in PAPS pregnancy.  
 
Conclusions:  
In terms of the clinical significance of the findings, the research suggests that 
the size of effects found are comparable to those observed in studies of cognitive 
impairment in patients with SLE who test positive for aPL antibodies. Furthermore, 
the prevalence of impairment in PAPS patients is comparable to that identified in a 
number of studies in SLE.  This patient group is acknowledged to have clinically 
significant deficits; these results highlight the clinical importance of cognitive deficits 
found in PAPS, particularly those with PAPS thrombosis. In addition, HRQoL in 
PAPS is poor and this too is comparable to other clinical populations, also 
highlighting the importance of a broad range of psychological, social, physical and 
somatic factors associated with chronic illness that are impaired in PAPS, some of 
which are associated with deficits in executive function and memory.  
 It is important to acknowledge potential confounding variables, such as 
disease activity, disease duration, coping style, social support and illness perceptions 
which may have explained the variance in HRQoL. When considering this in future 
research, it would also be prudent to address the importance of consistency in 
assessments such that studies are comparable and evidence is strengthened.   
The findings indicate the importance of monitoring cognitive functioning in 
this population in those with and without overt CNS involvement. It also emphasises 
the need for the provision of interventions such as cognitive rehabilitation and 
psychological therapies, both of which may facilitate improved adjustment and quality 
of life in patients with PAPS.    
 
Lucy Tinning 
Trainee Clinical Psychologist 
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Appendix P 
Cover Letter to the Hughes Syndrome Foundation re. Summary of Research Findings  
 
 
 
 
 
 
 
 
Clinical Psychology Programme 
Broomhill Road 
Tunbridge Wells 
Kent 
TN3 0TG 
 
Hughes Syndrome Foundation 
[Address] 
 
 
13th July 2011 
 
Study Title:   Cognitive functioning and quality of life in patients with      
Antiphospholipid Syndrome 
 
 
 
Dear Trustees 
 
Thank you very much indeed for providing funding for the above research on 16th 
June 2010. I am writing to inform you that data collection for the study has now 
been concluded. Please find attached a summary of the research and its findings. 
 
Please do not hesitate to contact me if you require any further information. 
 
 
Yours sincerely 
 
 
Lucy Tinning 
Trainee Clinical Psychologist 
Email: ljt29@canterbury.ac.uk 
 
 
 
Centre for Applied Social & Psychological Development 
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Appendix Q 
 
Summary of Research Findings for the Hughes Syndrome Foundation 
 
Research Summary: 
Cognitive Functioning and Quality of Life in Patients 
 with Antiphospholipid Syndrome 
 
Researcher: Lucy Tinning, Trainee Clinical Psychologist,  
       Canterbury Christ Church University 
Supervisors: Dr. Paul Camic, Professor Michael Kopelman 
 
Background and Aims:  
A clinical feature of Antiphospholipid syndrome (APS) is cognitive 
dysfunction which may be a direct manifestation of central nervous system (CNS) 
involvement.  Previous research has suggested that patients with aPL antibodies, APS 
and secondary APS (e.g. Systemic lupus erythematosus (SLE)-related APS) 
experience cognitive deficits which can vary from mild neurocognitive disorders to 
severe global dysfunction in the context of dementia. However, research in this area is 
limited and studies have mainly included SLE patients testing positive for aPL 
antibodies. Research distinguishing APS and secondary APS specifically is more 
limited and mainly anecdotal. Findings so far have not identified any consistent 
pattern of cognitive dysfunction although there are similarities in the deficits found. 
Deficits have been identified in patients with and without known CNS involvement in 
the disease. 
As an autoimmune disease, APS is a chronic illness and the range of clinical 
features of APS, including cognitive dysfunction, are likely to impact upon aspects of 
patients’ health related quality of life (HRQoL). Patients may be presented with 
changes in their life roles and social and familial relationships while they concurrently 
manage psychological distress, physical pain, ongoing medical treatment and 
restrictions in the activities of daily living.  
Research exploring cognitive dysfunction in APS or the experience of illness 
using HRQoL measures could not be found at the time of this study. Findings of 
research exploring HRQoL in similar clinical populations, such as SLE, indicate that 
scores on HRQoL measures have been 30-40% lower than those reported by matched 
peers with all domains of HRQoL affected.  
This study aimed to explore relationship between cognitive functioning and 
HRQoL in patients with APS. Further aims of this study were to establish the 
  114 
characteristics and prevalence of cognitive dysfunction and HRQoL in patients with 
APS. 
 
Study Design: 
A cross-sectional study was employed, utilising a quantitative design 
 
Participants: 
Thirty adult females with a diagnosis of APS were recruited from (Name of Service 
and Hospital), (NHS Trust Name). Fifteen participants had experienced pregnancy 
complications (with no known CNS involvement in the disease) and fifteen 
participants had experienced a thrombotic event (and are likely to have CNS 
involvement in the disease). Fifteen healthy females were also included as a control 
group. Patients with secondary APS were excluded from this study. 
 
Procedure: 
 Participants completed a range of self-report questionnaires and neuropsychological 
assessments designed to measure HRQoL and cognitive functioning across domains 
of general intelligence, executive functioning and memory. Statistical analyses were 
then conducted using the subscale and total scores on each measure for each 
participant. 
 
Results: 
Patients in the PAPS thrombosis group were twice as likely to be designated as 
cognitively impaired compared to patients in the PAPS pregnancy group. The findings 
also suggest that PAPS thrombosis patients had experienced a decrease in their 
general intellectual functioning compared to pre-morbid levels. This group also 
demonstrated lower performance on measures of memory and executive functioning 
compared to healthy controls. APS pregnancy patients also performed more poorly on 
these measures compared to healthy controls although not significantly. Both groups 
demonstrated poor HRQoL across physical and mental subscales. Both groups were 
significantly more impaired in all physical domains and one mental domain of 
HRQoL compared to controls. Neuropsychological outcomes in general intellectual 
abilities, memory and executive functioning were significantly associated with mental 
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HRQoL subscales in APS thrombosis and executive functioning and memory were 
significantly associated with physical HRQoL subscales in APS pregnancy.  
 
Conclusions:  
In terms of the clinical significance of the findings, the research suggests that the size 
of effects found are comparable to those observed in studies of cognitive impairment 
in patients with SLE who test positive for aPL antibodies. Furthermore, the 
prevalence of impairment in APS patients is comparable to that identified in a number 
of studies in SLE.  This patient group is acknowledged to have clinically significant 
deficits; these results highlight the clinical importance of cognitive deficits found in 
APS, particularly those with APS thrombosis. In addition, HRQoL in APS is poor and 
this too is comparable to other clinical populations, also highlighting the importance 
of a broad range of psychological, social, physical and somatic factors associated with 
chronic illness that are impaired in APS, some of which are associated with deficits in 
executive function and memory.  
 It is important to acknowledge potential confounding variables, such as 
disease activity, disease duration, coping style, social support and illness perceptions 
which may have explained the variance in HRQoL.  
The findings indicate the importance of monitoring cognitive functioning in 
this population in those with and without overt CNS involvement. It also emphasises 
the need for the provision of interventions such as cognitive rehabilitation and 
psychological therapies, both of which may facilitate improved adjustment and quality 
of life in patients with APS.    
 
Lucy Tinning 
Trainee Clinical Psychologist 
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Appendix R      Table 5A. Pearson or Spearman 1-tailed correlation between SF-36 subscales and neuropsychological outcomes 
  SF-36 Physical Functioninga SF-36 Role Physicala SF-36 Bodily Paina  SF-36 General Healtha SF-36 Vitalityb 
Cognitive Domain/ 
Neuropsychological outcomes r /  rs 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
General Intelligence            
WASI Vocabulary r    -0.57 * -0.44 -0.53* -0.31 -0.46* -0.37 -0.44 -0.31 -0.48* 0.01 
WASI Similarities r -0.17 -0.11 -0.24 -0.34 -0.21 -0.05 -0.12 -0.11 -0.11 0.07 
WASI Block Design r -0.38 0.03 -0.30 0.30 -0.18 -0.29 -0.24 -0.15 -0.48* -0.17 
WASI Matrix Reasoning r 0.15 -0.15 0.05 0.15 0.32 -0.16 0.18 -0.22 0.00 -0.42 
WASI Verbal IQ r -0.49* -0.34 -0.49* -0.36 -0.43 -0.31 -0.42 -0.30 -0.41 0.02 
WASI Performance IQ r -0.18 -0.01 -0.18 0.25 0.04 -0.24 -0.05 -0.19 -0.33 -0.28 
WASI Full-scale IQ r -0.49* -0.28 -0.49* -0.10 -0.32 -0.38 -0.36 -0.33 -0.55* -0.11 
Executive Functioning            
WAIS Digit Symbol Coding r 0.37 0.11 0.50* 0.07 0.31 -0.05 0.22 -0.19 0.14 -0.20 
WAIS Digit Span r 0.35 -0.33 0.41 -0.13 0.38 -0.04 0.52* -0.34 0.29 -0.21 
WAIS Symbol Search rs -0.26 -0.07 -0.07 -0.10 -0.29 -0.17 -0.51* -0.22 -0.59* -0.37 
DKEFS Letter Fluency r -0.01 -0.17 -0.17 -0.11 0.12 0.23 0.07 -0.10 -0.02 0.09 
DKEFS Category Fluency r -0.16 -0.26 -0.03 -0.35 -0.04 -0.13 -0.17 -0.17 -0.07 -0.27 
DKEFS Category Switching 
Responses r -0.03 -0.14 -0.03 0.13 0.31 0.13 0.13 0.03 -0.13 -0.10 
DKEFS Category Switching 
Accuracy r -0.14 -0.13 -0.16 0.15 0.22 0.12 0.02 -0.02 -0.23 -0.07 
DKEFS Trail Making 1 rs -0.05 -0.11 -0.29 0.07 0.09 -0.19 -0.33 -0.12 -0.01 -0.05 
DKEFS Trail Making 2 rs 0.06 -0.43 0.14 -0.25 0.31 -0.28 0.28 0.58* 0.13 0.56* 
DKEFS Trail Making 3 rs 0.03 -0.31 0.09 -0.08 -0.09 -0.09 -0.15 -0.39 -0.04 -0.41 
DKEFS Trail Making 4 rs 0.27 -0.06   0.49* -0.03 0.03 -0.02 0.40 0.02 0.37 -0.16 
DKEFS Trail Making 5 rs -0.42 -0.12 -0.30 -0.17 -0.21 -0.31 -0.23 -0.44 -0.02 -0.40 
DKEFS Composite Score rs 0.17 -0.42 0.34 -0.18 -0.05 -0.11 0.31 -0.47* 0.25 -0.47* 
Memory            
Camden Memory Test Faces rs 0.50* 0.34 0.59** 0.31 0.20 0.39 0.19 0.39 0.22 0.41 
Camden Memory Test Words rs 0.32 0.11 0.28 -0.04 -0.11 0.07 0.05 0.03 0.09 0.14 
BIRT Story Recall Immediate r 0.03 0.00 -0.04 -0.19 0.15 -0.04 0.40 0.28 0.03 0.01 
BIRT Story Recall Delayed r 0.03 -0.25 -0.01 -0.22 0.23 -0.22 .470* 0.08 0.06 -0.16 
BIRT Figure Recall Immediate r 0.00 -0.39 -0.08 0.05 0.29 -0.49* 0.05 -0.38 0.28 -0.42 
BIRT Figure Recall Delayed r 0.04 -0.13 -0.04 0.13 0.28 -0.49* 0.06 -0.37 0.39 -0.41 
Graded Naming rs -0.43 0.26 -0.46* -0.16 -0.94 1.45 -0.30 -0.40 -0.59** 0.40 
a: PCS ; b: MCS *** < .000; ** < .01; * <.05 
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Appendix R      Table 5B. Pearson or Spearman correlation between SF-36 subscales and neuropsychological outcomes 
   
SF-36 Social Functioningb SF-36 Role Emotionalb SF-36 Mental Healthb SF-36 Physical Component Score 
SF-36 Mental Component 
Score 
Cognitive Domain/ 
Neuropsychological outcomes r /  rs 
PAPS 
Pregnancy  
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
PAPS 
Pregnancy 
PAPS 
Thrombosis 
General Intelligence            
WASI Vocabulary r -0.42 -0.39 0.10 -0.47* -0.01 -0.02 -.060** -0.17 0.07 -0.17 
WASI Similarities r -0.09 -0.26 0.22 -0.28 0.31 0.29 -0.29 0.05 0.30 0.01 
WASI Block Design r -0.42 -0.12 0.29 0.48* 0.00 0.00 -0.36 -0.02 -0.01 0.21 
WASI Matrix Reasoning r 0.11 -0.22 0.33 .517* -0.02 -0.06 0.16 -0.14 0.07 0.18 
WASI Verbal IQ r -0.35 -0.35 0.16 -0.38 0.10 0.07 -0.57* -0.08 0.16 -0.09 
WASI Performance IQ r -0.23 -0.14 0.43 0.58* 0.01 0.00 -0.17 -0.07 0.06 0.26 
WASI Full-scale IQ r -0.43 -0.35 0.36 0.03 0.07 0.09 -0.55* -0.08 0.14 0.10 
Executive Functioning              
WAIS Digit Symbol Coding r 0.32 -0.35 0.35 0.39 0.17 0.12 0.36 -0.12 0.12 0.11 
WAIS Digit Span r 0.11 -0.04 0.11 0.41 0.33 0.50* 0.41 -0.13 0.09 0.59* 
WAIS Symbol Search rs -0.29 -0.15 0.31 0.24 -0.08 0.01 -0.34 -0.12 -0.12 0.15 
DKEFS Letter Fluency r -0.04 0.09 0.02 -0.01 -0.28 0.05 0.02 -0.13 -0.11 0.10 
DKEFS Category Fluency r -0.05  - 0.58* 0.34 0.09 -0.03 0.35 -0.14 -0.20 0.13 0.16 
DKEFS Category Switching 
Responses r -0.25 -0.07 -0.23 0.37 -0.48* 0.26 0.17 -0.06 -.047* 0.31 
DKEFS Category Switching 
Accuracy r -0.32 -0.05 -0.24 0.39 -0.47* 0.31 0.04 -0.04 -0.45* 0.37 
DKEFS Trail Making 1 rs -0.12 -0.05 -0.31 0.29 -0.05 0.33 -0.09 -0.28 -0.17 0.51* 
DKEFS Trail Making 2 rs -0.06 -0.12 0.01 0.20 0.07 -0.02 0.30 -0.36 -0.05 0.17 
DKEFS Trail Making 3 rs -0.06 0.10 0.05 0.29 0.28 0.18 -0.08 -0.41 0.00 0.38 
DKEFS Trail Making 4 rs 0.17 -0.22 0.26 0.23 0.57* 0.15 0.30 -0.18 0.36 0.26 
DKEFS Trail Making 5 rs 0.00 -0.22 0.25 -0.09 -0.04 -0.06 -0.40 -0.16 0.21 -0.05 
DKEFS Composite Score rs 0.22 0.06 0.28 0.17 0.37 -0.03 0.14 -0.44 0.33 0.18 
Memory            
Camden Memory Test Faces rs 0.28 0.55* 0.20 0.41 0.07 0.38 0.32 0.56* 0.03 0.47* 
Camden Memory Test Words rs 0.16 -0.23 0.60** -0.34 0.48* 0.11 0.00 0.11 0.45* -0.16 
BIRT Story Recall Immediate r 0.06 -0.03 -0.06 0.07 0.09 0.00 0.10 0.05 0.06 0.57  
BIRT Story Recall Delayed r 0.06 -0.19 -0.09 0.03 -0.01 0.01 0.16 -0.12 -0.01 0.07 
BIRT Figure Recall Immediate r -0.01 -0.39 -0.24 0.18 0.01 -0.38 0.07 -0.18 0.01 -0.11 
BIRT Figure Recall Delayed r 0.17 -0.47* -0.05 0.45* 0.14 -0.05 0.07 -0.14 0.23 0.12 
Graded Naming rs -0.25 -0.02 0.26 -0.26 -0.22 0.18 -0.33 0.38 -0.11 -0.10 
a: PCS ; b: MCS *** < .000; ** < .01; * <.05         
 Appendix S 
Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999) 
 
This has been removed from the electronic copy 
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Appendix T 
Wechsler Adult Intelligence Scale III (WAIS III UK; Wechsler, 1998) - subtests:  
i) Digit Symbol Coding ii) Digit Span iii) Symbol Search (pages 1- 2) 
 
i) Digit Symbol Coding 
 
This has been removed from the electronic copy 
 
ii) Digit Span 
 
This has been removed from the electronic copy 
 
iii) Symbol Search (page 1) 
This has been removed from the electronic copy 
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Appendix U 
 
The National Adult Reading Test (NART; Nelson, 1982) 
 
 
This has been removed from the electronic copy 
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Appendix V 
 
Delis Kaplan Executive Function System (DKEFS; Delis, Kaplan & Kramer, 2001) Verbal 
Fluency Test 
 
 
This has been removed from the electronic copy 
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Appendix W 
 
 Delis Kaplan Executive Function System (DKEFS; Delis, Kaplan & Kramer, 2001) – Trail 
Making Test Conditions 1 to 5 (front pages) 
 
This has been removed from the electronic copy 
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Appendix X 
 
Delis Kaplan Executive Function System (DKEFS; Delis, Kaplan & Kramer, 2001) Trail 
Making Test Score Form 
 
 
This has been removed from the electronic copy 
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Appendix Y 
 
The Brain Injury and Rehabilitation Trust (BIRT) Memory and Information Processing 
Battery (BMIPB; Oddy, Coughlan & Crawford, 2007) – Story Recall Form 1 
 
 
This has been removed from the electronic copy 
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Appendix Z 
 
The Brain Injury and Rehabilitation Trust (BIRT) Memory and Information Processing 
Battery (BMIPB; Oddy, Coughlan & Crawford, 2007) – Figure Recall Form 1 
 
 
This has been removed from the electronic copy 
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Appendix Z1 
 
Camden Memory Tests - Short Recognition Memory Test for Words and Faces 
 
This has been removed from the electronic copy 
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Appendix Z2 
Graded Naming Test (GNT; McKenna & Warrington, 1983)  
This has been removed from the electronic copy 
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Appendix Z3 
Medical Outcomes Survey Short Form-36 (SF-36; Ware & Sherbourne, 1992) 
This has been removed from the electronic copy 
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Appendix Z4 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith1983) 
 
This has been removed from the electronic copy 
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Appendix Z5 
Tests for Normal Distribution and Homogeneity of Variance 
 
The distributions for each total scale and each subscale were identified by examining 
Kolmogorov-Smirnov test scores. Scores that were significant indicated that the distribution 
of the sample was significantly different from a normal distribution.  
 
Homogeneity of variance was identified by examining Levene’s test for each total scale and 
subscale. Significant tests indicate that variances differ significantly between the groups.  
 
Significance in either of these tests suggests assumptions of normality and/or homogeneity of 
variance have been violated and that non-parametric tests are appropriate. 
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1). Demographic and Clinical Characteristics of the PAPS patients and Controls 
 
 
Kolmogorov-Smirnov Tests of Normality: Demographic and Clinical Characteristics 
 
Kolmogorov-Smirnov  
 
  
Group 
Statistic df Sig. 
PAPS Pregnancy .121 15 .200 
PAPS Thrombosis .196 15 .125 Age 
Control .248 15    .014* 
PAPS Pregnancy .183 15 .188 
PAPS Thrombosis .241 15   .019* Premorbid Full Scale IQ - NART 
Control .144 15 .200 
PAPS Pregnancy .141 15 .200 
PAPS Thrombosis .143 15 .200 HADS Depression Score 
Control .231 15   .031* 
PAPS Pregnancy .233 15  .027* 
PAPS Thrombosis .220 15 .050 Number of Years Education 
Control .328 15  .000* 
*** <.000; ** < .01; * <.05     
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Levene’s Test of Homogeneity of Variance: Demographic and Clinical 
Characteristics 
 
  
  
Levene 
Statistic df1 df2 Sig. 
Based on Mean 4.861 2 42 .013* 
Based on Median 1.413 2 42 .255 
Based on Median and 
with adjusted df 1.413 2 25.080 .262 
Age 
Based on trimmed 
mean 
3.999 2 42 .026 
Based on Mean .841 2 42 .439 
Based on Median .521 2 42 .598 
Based on Median and 
with adjusted df .521 2 26.791 .600 
Premorbid Full Scale 
IQ using NART error 
score 
Based on trimmed 
mean 
.749 2 42 .479 
Based on Mean .741 1 28 .397 
Based on Median .551 1 28 .464 
Based on Median and 
with adjusted df .551 1 26.737 .464 
HADS Depression 
Score 
Based on trimmed 
mean 
.756 1 28 .392 
Based on Mean 2.488 2 42 .095 
Based on Median .634 2 42 .535 
Based on Median and 
with adjusted df .634 2 29.398 .537 
Number of years 
education 
Based on trimmed 
mean 
2.296 2 42 .113 
*** <.000; ** < .01; * <.05 
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2. Neuropsychological outcomes 
 
2a. Neuropsychological outcomes – General Intelligence  
 
 
Kolmogorov-Smirnov Tests of Normality : WASI  
 
Kolmogorov-Smirnov 
  
  
Group 
Statistic df Sig. 
PAPS Pregnancy .194 15 .133 
PAPS Thrombosis .176 15 .200 WASI Vocabulary Scaled Score 
Control .210 15 .073 
PAPS Pregnancy .136 15 .200 
PAPS Thrombosis .163 15 .200 WASI Block Design Scaled Score 
Control .213 15 .067 
PAPS Pregnancy .228 15 .057 
PAPS Thrombosis .180 15 .200 WASI Similarities Scaled Score 
Control .128 15 .200 
PAPS Pregnancy .222 15 .200 
PAPS Thrombosis .197 15 .122 WASI Matrix Reasoning Scaled Score 
Control .185 15 .175 
PAPS Pregnancy .119 15 .200 
PAPS Thrombosis .140 15 .200 WASI Verbal IQ 
Control .203 15 .095 
PAPS Pregnancy .128 15 .200 
PAPS Thrombosis .142 15 .200 WASI Performance IQ 
Control .178 15 .200 
PAPS Pregnancy .137 15 .200 
PAPS Thrombosis .116 15 .200 WASI Full scale IQ 
Control .144 15 .200 
*** <.000; ** < .01; * <.05 
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Levene’s Test of Homogeneity of Variance: WASI 
 
    
Levene 
Statistic df1 df2 Sig. 
Based on Mean .696 2 42 .504 
Based on Median .391 2 42 .679 
Based on Median 
and with adjusted 
df 
.391 2 23.295 .681 
WASI Vocabulary Scaled Score 
Based on trimmed 
mean 
.446 2 42 .643 
Based on Mean .854 2 42 .433 
Based on Median .972 2 42 .387 
Based on Median 
and with adjusted 
df 
.972 2 28.571 .390 
WASI Block Design Scaled 
 Score 
Based on trimmed 
mean 
.941 2 42 .398 
Based on Mean .225 2 42 .799 
Based on Median .321 2 42 .727 
Based on Median 
and with adjusted 
df 
.321 2 39.858 .727 
WASI Similarities Scaled Score 
Based on trimmed 
mean 
.241 2 42 .787 
Based on Mean .012 2 42 .988 
Based on Median .009 2 42 .992 
Based on Median 
and with adjusted 
df 
.009 2 38.525 .992 
WASI Matrix Reasoning Scaled 
Score 
Based on trimmed 
mean 
.014 2 42 .986 
Based on Mean .624 2 42 .541 
Based on Median .416 2 42 .662 
Based on Median 
and with adjusted 
df 
.416 2 36.474 .663 
WASI Verbal IQ 
Based on trimmed 
mean 
.597 2 42 .555 
*** <.000; ** < .01; * <.05 
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Levene’s Test of Homogeneity of Variance: WASI continued 
 
  
Levene 
Statistic df1 df2 Sig. 
Based on Mean .177 2 42 .839 
Based on Median .204 2 42 .816 
Based on Median 
and with adjusted 
df 
.204 2 37.846 .816 
WASI Performance IQ 
Based on trimmed 
mean 
.204 2 42 .817 
Based on Mean 1.633 2 42 .208 
Based on Median 1.420 2 42 .253 
Based on Median 
and with adjusted 
df 
1.420 2 41.501 .253 WASI Full scale IQ 
Based on trimmed 
mean 
1.634 2 42 .207 
*** <.000; ** < .01; * <.05      
  
 
2b Neuropsychological outcomes – Executive Functioning 
 
Kolmogorov-Smirnov Tests of Normality:  WAIS subtests 
 
Kolmogorov-Smirnov 
  
  
Group 
Statistic df Sig. 
PAPS Pregnancy .227 15 .133 
PAPS Thrombosis .155 15 .200 WAIS Digit Symbol Coding Scaled Score 
Control .127 15 .200 
PAPS Pregnancy .209 15 .076 
PAPS Thrombosis .175 15 .200 WAIS Digit Span Scaled Score 
Control .167 15 .200 
PAPS Pregnancy .212 15 .067 
PAPS Thrombosis .242 15 .018* WAIS Symbol Search Scaled Score 
Control .175 15 .200 
*** <.000; ** < .01; * <.05 
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Kolmogorov-Smirnov Tests of Normality:  DKEFS Fluency Tests 
 
Kolmogorov-Smirnov 
 Group 
Statistic df Sig. 
PAPS Pregnancy .115 15 .200 
PAPS Thrombosis .157 15 .200 DKEFS Letter Fluency Scaled Score 
Control .151 15 .200 
PAPS Pregnancy .150 15 .200 
PAPS Thrombosis .184 15 .183 DKEFS Category Fluency Scaled Score 
Control .211 15 .071 
PAPS Pregnancy .171 15 .200 
PAPS Thrombosis .127 15 .200 DKEFS Category Switching Responses Scaled Score 
Control .184 15 .182 
PAPS Pregnancy .204 15 .094 
PAPS Thrombosis .158 15 .200 
 
 
DKEFS Category Switching Accuracy 
Scaled Score 
Control .122 15 .200 
     
     
     
     
     
     
     
     
     
     
     
     
     
*** <.000; ** < .01; * <.05 
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Kolmogorov-Smirnov Tests of Normality: DKEFS Trail Making Tests 
 
 Kolmogorov-Smirnov 
 Group 
Statistic df Sig. 
PAPS Pregnancy .175 15 .200 
PAPS Thrombosis .310 15 .000*** DKEFS Trail Making Condition 1 Scaled Score 
Control .222 15 .046* 
PAPS Pregnancy .246 15 .015* 
PAPS Thrombosis .156 15 .200 DKEFS Trail Making Condition 2 Scaled Score 
Control .195 15 .129 
PAPS Pregnancy .294 15 .001** 
PAPS Thrombosis .159 15 .200 DKEFS Trail Making Condition 3 Scaled Score 
Control .321 15 .000*** 
PAPS Pregnancy .208 15 .079 
PAPS Thrombosis .234 15 .027* DKEFS Trail Making Condition 4 Scaled Score 
Control .186 15 .171 
PAPS Pregnancy .152 15 .200 
PAPS Thrombosis .177 15 .200 DKEFS Trail Making Condition 5 Scaled Score 
Control .241 15 .019* 
PAPS Pregnancy .215 15 .038* 
PAPS Thrombosis .119 15 .200 DKEFS Condtion 2 plus Condition 3 Scaled Composite Score 
Control .147 15 .200 
*** <.000; ** < .01; * <.05 
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Levene’s Test of Homogeneity of Variance: WAIS subtests 
 
    
Levene 
Statistic df1 df2 Sig. 
Based on Mean 2.642 2 42 .083 
Based on 
Median 2.104 2 42 .135 
Based on 
Median and 
with adjusted df 
2.104 2 18.726 .150 
WAIS Digit Symbol 
Coding Scaled Score 
Based on 
trimmed mean 2.477 2 42 .096 
Based on Mean .307 2 42 .737 
Based on 
Median .331 2 42 .720 
Based on 
Median and 
with adjusted df 
.331 2 40.987 .720 
WAIS Digit Span 
Scaled Score 
Based on 
trimmed mean .290 2 42 .750 
Based on Mean 1.081 2 42 .348 
Based on 
Median .331 2 42 .720 
Based on 
Median and 
with adjusted df 
.331 2 24.250 .721 
WAIS Symbol Search 
Scaled Score 
Based on 
trimmed mean .849 2 42 .435 
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Levene’s Test of Homogeneity of Variance: DKEFS Fluency Test 
  
Levene 
Statistic df1 df2 Sig. 
Based on Mean 1.734 2 42 .189 
Based on 
Median 1.601 2 42 .214 
Based on 
Median and 
with adjusted df 
1.601 2 40.011 .214 
DKEFS Letter Fluency 
Scaled Score 
Based on 
trimmed mean 1.728 2 42 .190 
Based on Mean .249 2 42 .781 
Based on 
Median .306 2 42 .738 
Based on 
Median and 
with adjusted df 
.306 2 41.637 .738 
DKEFS Category 
Fluency Scaled Score 
Based on 
trimmed mean .233 2 42 .793 
Based on Mean 1.789 2 42 .180 
Based on 
Median 1.256 2 42 .295 
Based on 
Median and 
with adjusted df 
1.256 2 19.241 .307 
DKEFS Category 
Switching Responses 
Scaled Score 
Based on 
trimmed mean 1.648 2 42 .205 
Based on Mean 2.084 2 42 .137 
Based on 
Median 1.559 2 42 .222 
Based on 
Median and 
with adjusted df 
1.559 2 27.616 .228 
DKEFS Category 
Switching Accuracy 
Scaled Score 
Based on 
trimmed mean 1.862 2 42 .168 
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Levene’s Test of Homogeneity of Variance: DKEFS Trail Making Tests 
  
Levene 
Statistic df1 df2 Sig. 
Based on Mean 8.376 2 42 .001* 
Based on 
Median 1.854 2 42 .169 
Based on 
Median and 
with adjusted df 
1.854 2 16.522 .188 
DKEFS Trail Making 
Condition 1 Scaled 
Score 
Based on 
trimmed mean 5.781 2 42 .006* 
Based on Mean 3.666 2 42 .034* 
Based on 
Median 2.989 2 42 .061 
Based on 
Median and 
with adjusted df 
2.989 2 20.765 .072 
DKEFS Trail Making 
Condition 2 Scaled 
Score 
Based on 
trimmed mean 3.233 2 42 .049* 
Based on Mean 4.266 2 42 .021* 
Based on 
Median 2.932 2 42 .064 
Based on 
Median and 
with adjusted df 
2.932 2 19.510 .077 
DKEFS Trail Making 
Condition 3 Scaled 
Score 
Based on 
trimmed mean 3.630 2 42 .035* 
Based on Mean 2.377 2 42 .105 
Based on 
Median .835 2 42 .441 
Based on 
Median and 
with adjusted df 
.835 2 30.244 .444 
DKEFS Trail Making 
Condition 4 Scaled 
Score 
Based on 
trimmed mean 1.720 2 42 .192 
Based on Mean 2.834 2 42 .070 
Based on 
Median 2.606 2 42 .086 
Based on 
Median and 
with adjusted df 
2.606 2 25.185 .094 
DKEFS Trail Making 
Condition 5 Scaled 
Score 
Based on 
trimmed mean 2.880 2 42 .067 
*** <.000; ** < .01; * <.05 
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2c Neuropsychological outcomes - Memory 
 
Kolmogorov-Smirnov Tests of Normality: BIRT Story and Figure Recall 
 
Kolmogorov-Smirnov 
  
  
Group 
Statistic df Sig. 
PAPS Pregnancy .134 14 .200 
PAPS Thrombosis .194 15 .133 BIRT Story Recall Immediate Scaled Score 
Control .171 15 .200 
PAPS Pregnancy .161 14 .200 
PAPS Thrombosis .209 15 .076 BIRT Story Recall Scaled Score 
Control .200 15 .108 
PAPS Pregnancy .151 14 .200 
PAPS Thrombosis .124 15 .200 BIRT Figure Recall immediate Scaled Score 
Control .212 15 .070 
PAPS Pregnancy .136 14 .200 
PAPS Thrombosis .173 15 .200 BIRT Figure Recall Delayed Scaled Score 
Control .163 15 .200 
*** <.000; ** < .01; * <.05 
    
     
     
Kolmogorov-Smirnov Tests of Normality: Camden Memory Tests  
 
 
Kolmogorov-Smirnov 
 Group 
Statistic df Sig. 
PAPS Pregnancy .510 14 .000*** 
PAPS Thrombosis .430 15 .000*** Camden Memory Test Words Scaled Score 
Control .514 15 .000*** 
PAPS Pregnancy .510 14 .000*** 
PAPS Thrombosis .253 15 .011* Camden Memory Test Faces Scaled Score 
Control .535 15 .000*** 
*** <.000; ** < .01; * <.05 
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Kolmogorov-Smirnov Tests of Normality: Graded Naming Tests 
 
Kolmogorov-Smirnov 
 Group 
Statistic df Sig. 
PAPS Pregnancy .164 14 .200 
PAPS Thrombosis .224 15 .041* Warrington McKenna Graded Naming Scaled Score  
Control .242 15 .019* 
*** <.000; ** < .01; * <.05 
    
  
Levene’s Test of Homogeneity of Variance: BIRT Story and Figure 
Recall 
 
    
Levene 
Statistic df1 df2 Sig. 
Based on Mean .440 2 41 .647 
Based on Median .450 2 41 .641 
Based on Median 
and with adjusted 
df 
.450 2 40.579 .641 
BIRT Story Recall 
Immediate Scaled 
Score 
Based on trimmed 
mean 
.442 2 41 .646 
Based on Mean 1.197 2 41 .313 
Based on Median .431 2 41 .653 
Based on Median 
and with adjusted 
df 
.431 2 39.361 .653 BIRT Story recall Scaled Score 
Based on trimmed 
mean 
1.154 2 41 .325 
Based on Mean 1.979 2 41 .151 
Based on Median .925 2 41 .405 
Based on Median 
and with adjusted 
df 
.925 2 17.147 .415 
BIRT Figure recall 
immediate Scaled 
Score 
Based on trimmed 
mean 
1.371 2 41 .265 
Based on Mean 2.027 2 41 .145 
Based on Median 1.063 2 41 .355 
Based on Median 
and with adjusted 
df 
1.063 2 31.088 .357 
BIRT Figure Recall 
Delayed Scaled 
Score 
Based on trimmed 
mean 
1.746 2 41 .187 
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Levene’s Test of Homogeneity of Variance: Camden Memory Tests 
  
Levene 
Statistic df1 df2 Sig. 
Based on Mean 4.638 2 41 .015* 
Based on Median 1.438 2 41 .249 
Based on Median 
and with adjusted 
df 
1.438 2 16.379 .266 
Camden Memory 
Test Words Scaled 
Score 
Based on trimmed 
mean 
2.880 2 41 .068 
Based on Mean 16.564 2 41 .000*** 
Based on Median 7.862 2 41 .001** 
Based on Median 
and with adjusted 
df 
7.862 2 18.416 .003** 
Camden Memory 
Test Faces Scaled 
Score 
Based on trimmed 
mean 
14.645 2 41 .000*** 
*** <.000; ** < .01; * <.05 
     
 
     
 
     
Levene’s Test of Homogeneity of Variance: Graded Naming Test 
  
Levene 
Statistic df1 df2 Sig. 
Based on Mean .042 2 41 .959 
Based on Median .041 2 41 .960 
Based on Median 
and with adjusted 
df 
.041 2 35.746 .960 
Warrington 
McKenna Graded 
Naming Scaled Score 
Based on trimmed 
mean 
.052 2 41 .950 
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* <.000; ** < .01; * <.05 
3. SF-36 Subscales and Mental Component Score and Physical Component Score 
 
Kolmogorov-Smirnov Tests of Normality : SF-36  
Kolmogorov-Smirnova 
 
Group 
Statistic df Sig. 
PAPS Pregnancy .217 15 .056 
PAPS Thrombosis .179 15 .200 SF 36 Physical Functioning Norms Based score 0-100
Control .335 15 .000*** 
PAPS Pregnancy .191 15 .147 
PAPS Thrombosis .122 15 .200 SF 36 Role Physical Norms Based score 0-100 
Control .500 15 .000*** 
PAPS Pregnancy .220 15 .049* 
PAPS Thrombosis .170 15 .200 SF 36 Bodily Pain Norms Based score 0-100 
Control .302 15 .001** 
PAPS Pregnancy .185 15 .176 
PAPS Thrombosis .225 15 .039* SF 36 General Health Norms Based score 0-100 
Control .172 15 .200 
PAPS Pregnancy .152 15 .200 
PAPS Thrombosis .197 15 .123 SF 36 Vitality Norms Based 
score 0-100 
Control .163 15 .200 
PAPS Pregnancy .229 15 .033* 
PAPS Thrombosis .232 15 .029* SF 36 Social Functioning Norms Based score 0-100 
Control .355 15 .000*** 
PAPS Pregnancy .215 15 .061 
PAPS Thrombosis .207 15 .082 SF 36 Role Emotional Norms Based score 0-100 
Control .245 15 .016* 
PAPS Pregnancy .125 15 .200 
PAPS Thrombosis .151 15 .200 SF 36 Mental Health Norms Based score 0-100 
Control .162 15 .200 
PAPS Pregnancy .184 15 .181 
PAPS Thrombosis .143 15 .200 SF 36 Physical Component 
score 
Control .124 15 .200 
PAPS Pregnancy .147 15 .200 
PAPS Thrombosis .120 15 .200 
SF 36 Mental Component 
score 
Control .241 15 .019* 
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Levene’s Test of Homogeneity of Variance: SF-36 
 
  
Levene 
Statistic df1 df2 Sig. 
Based on Mean 6.223 2 42 .004* 
Based on Median 4.086 2 42 .024* 
Based on Median and 
with adjusted df 4.086 2 21.821 .031* 
SF 36 Physical Functioning 
Norms Based score 0-100 
Based on trimmed 
mean 
5.322 2 42 .009* 
Based on Mean 7.658 2 42 .001** 
Based on Median 6.327 2 42 .004** 
Based on Median and 
with adjusted df 6.327 2 32.331 .005** 
SF 36 Role Physical Norms 
Based score 0-100 
Based on trimmed 
mean 
7.961 2 42 .001** 
Based on Mean 6.385 2 42 .004** 
Based on Median 2.595 2 42 .087 
Based on Median and 
with adjusted df 2.595 2 35.536 .089 
SF 36 Bodily Pain Norms 
Based score 0-100 
Based on trimmed 
mean 
6.173 2 42 .004** 
Based on Mean 11.349 2 42 .000*** 
Based on Median 4.485 2 42 .017* 
Based on Median and 
with adjusted df 4.485 2 29.232 .020* 
SF 36 General Health Norms 
Based score 0-100 
Based on trimmed 
mean 
10.511 2 42 .000*** 
Based on Mean 2.506 2 42 .094 
Based on Median 2.011 2 42 .147 
Based on Median and 
with adjusted df 2.011 2 36.839 .148 
 
 
 
 
SF 36 Vitality Norms Based 
score 0-100 
 
Based on trimmed 
mean 
2.355 2 42 .107 
*** <.000; ** < .01; * <.05 
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Levene’s Test of Homogeneity of Variance: SF-36 continued 
 
 
Levene 
Statistic df1 df2 Sig. 
Based on Mean 2.048 2 42 .142 
Based on Median 1.270 2 42 .291 
Based on Median and 
with adjusted df 1.270 2 33.577 .294 
SF 36 Social Functioning 
Norms Based score 0-100 
Based on trimmed 
mean 
1.504 2 42 .234 
Based on Mean 3.728 2 42 .032* 
Based on Median 1.672 2 42 .200 
Based on Median and 
with adjusted df 1.672 2 25.730 .208 
SF 36 Role Emotional Norms 
Based score 0-100 
Based on trimmed 
mean 
2.884 2 42 .067 
Based on Mean .381 2 42 .686 
Based on Median .309 2 42 .736 
Based on Median and 
with adjusted df .309 2 41.638 .736 
SF 36 Mental Health Norms 
Based score 0-100 
Based on trimmed 
mean 
.405 2 42 .670 
Based on Mean 3.879 2 42 .028* 
Based on Median 2.207 2 42 .123 
Based on Median and 
with adjusted df 2.207 2 21.346 .135 
SF 36 Physical Component 
score 
Based on trimmed 
mean 
3.096 2 42 .056 
Based on Mean .167 2 42 .847 
Based on Median .037 2 42 .964 
Based on Median and 
with adjusted df .037 2 24.021 .964 
SF 36 Mental Component 
score 
Based on trimmed 
mean 
.038 2 42 .962 
*** <.000; ** < .01; * <.05 
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  149 
• Authors are responsible for acquiring written permission to publish lengthy quotations, 
illustrations, etc. for which they do not own copyright.  
For guidelines on editorial style, please consult the APA Publication Manual published by the American 
Psychological Association.  
6. Supporting Information  
JNP is happy to accept articles with supporting information supplied for online only publication. This 
may include appendices, supplementary figures, sound files, videoclips etc. These will be posted on 
Wiley Online Library with the article. The print version will have a note indicating that extra material 
is available online. Please indicate clearly on submission which material is for online only publication. 
Please note that extra online only material is published as supplied by the author in the same file 
format and is not copyedited or typeset. Further information about this service can be found at 
http://authorservices.wiley.com/bauthor/suppmat.asp. 
7. Copyright  
Authors will be required to assign copyright to The British Psychological Society. Copyright 
assignment is a condition of publication and papers will not be passed to the publisher for production 
unless copyright has been assigned. To assist authors an appropriate copyright assignment form will 
be supplied by the editorial office and is also available on the journal’s website at 
http://www.blackwellpublishing.com/pdf/CTA_BPS.pdf. Government employees in both the US 
and the UK need to complete the Author Warranty sections, although copyright in such cases does 
not need to be assigned.  
8. Colour illustrations  
At the editors’ discretion, colour figures can be provided for use in the journal. Good quality 
photographs will be considered for inclusion where they add substantially to the argument, to a 
maximum of three per article. These can be supplied electronically as TIF files scanned to at least 
300dpi. If they are not printed in colour, then they can be reproduced in colour online and black and 
white in print.  
9. Pre-submission English-language editing  
Authors for whom English is a second language may choose to have their manuscript professionally 
edited before submission to improve the English. A list of independent suppliers of editing services 
can be found at http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for 
and arranged by the author, and use of one of these services does not guarantee acceptance or 
preference for publication.  
10. Author Services  
Author Services enables authors to track their article – once it has been accepted – through the 
production process to publication online and in print. Authors can check the status of their articles 
online and choose to receive automated e-mails at key stages of production. The author will receive 
an e-mail with a unique link that enables them to register and have their article automatically added 
to the system. Please ensure that a complete e-mail address is provided when submitting the 
manuscript. Visit http://authorservices.wiley.com/bauthor/ for more details on online production 
tracking and for a wealth of resources including FAQs and tips on article preparation, submission and 
more.  
11. The Later Stages  
  150 
The corresponding author will receive an email alert containing a link to a web site. A working e-mail 
address must therefore be provided for the corresponding author. The proof can be downloaded as a 
PDF (portable document format) file from this site. Acrobat Reader will be required in order to read 
this file. This software can be downloaded (free of charge) from the following web site: 
http://www.adobe.com/products/acrobat/readstep2.html. This will enable the file to be opened, read on 
screen and annotated direct in the PDF. Corrections can also be supplied by hard copy if preferred. 
Further instructions will be sent with the proof. Hard copy proofs will be posted if no e-mail address 
is available. Excessive changes made by the author in the proofs, excluding typesetting errors, will be 
charged separately.  
12. Early View  
Journal of Neuropsychology is covered by the Early View service on Wiley Online Library. Early View 
articles are complete full-text articles published online in advance of their publication in a printed 
issue. Articles are therefore available as soon as they are ready, rather than having to wait for the 
next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, 
revised and edited for publication, and the authors’ final corrections have been incorporated. 
Because they are in final form, no changes can be made after online publication. The nature of Early 
View articles means that they do not yet have volume, issue or page numbers, so they cannot be 
cited in the traditional way. They are cited using their Digital Object Identifier (DOI) with no volume 
and issue or pagination information. E.g., Jones, A.B. (2010). Human rights Issues. Human Rights 
Journal. Advance online publication. doi:10.1111/j.1467-9299.2010.00300.x  
Further information about the process of peer review and production can be found in this document. 
What happens to my paper? 
 
 
 
 
 
